ZANA Ilan
DFASP2
Année 2018-2019

UNIVERSITÉ PARIS DESCARTES

Rapport de stage d'application de DFASP2

LIMICS

Instituts thématiques

Inserm
Institut national
de la santé et de la recherche médicale

Maître de stage : Jean CHARLET

LIMICS, Inserm U11 42

1 Table des matières

2 Liste des abréviations

HeTOP : Health Terminology/Ontology Portal

ANR : Agence Nationale de Recherche

AMM : Autorisation de Mise sur le Marché

MeSH : Medical Subject Headings

PMID : Pubmed Identifier

LIMICS : Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé

CISMeF : Catalogue et Index des Sites Médicaux de langue Française

CRBM : Constructeur de Requêtes Bibliographiques Médicales

RTU : Recommandations Temporaires d'Utilisation

PsyHAMM : Usage des médicaments Psychiatriques Hors Autorisation de Mise sur le Marché

ANSM : Agence Nationale de Sécurité du Médicament et des produits de santé

ARS : Agence Régionale de Santé

CHSA : Centre Hospitalier Saint-Anne

SIH : Système d'Information Hospitalier

ECMT : Extracteur de Concepts Multi-Terminologique

OnBaSAM : Ontology-Based Semantic Annotation Module

CIP : Code Identifiant de Présentation

CIS : Code Identifiant de Spécialité

UCD : Unité Commune de Dispensation

ATC : Anatomical Therapeutic Chemical Classification System

Inserm : Institut National de la Santé et de la Recherche Médicale

CHU : Centre Hospitalo-Universitaire

3 Liste des figures

4 Liste des tableaux

5 Texte

5.1 L'Inserm

Créé en 1964, l'Institut National de la Santé et de la Recherche Médicale (Inserm) est un établissement public à caractère scientifique et technologique sous la tutelle du ministère de la Santé et du ministère de la Recherche. Il se consacre à la recherche biologique, médicale et la santé humaine. Il est le partenaire des plus grandes institutions engagées dans les défis et progrès scientifiques de ces domaines. L'Inserm est à l'origine de plus de 11 000 publications scientifiques. C'est le premier déposant de brevets à échelle européenne dans le secteur pharmaceutique et biomédical, 4e dans le secteur des biotechnologies.
Il possède 281 unités de recherche, 36 centres d'investigation clinique et 34 unités de service en France. À l'étranger, il est associé à 29 laboratoires internationaux, possède 2 unités de recherche et représente plus de 6 000 coopérations avec des partenaires internationaux.

En 2008, l'Inserm crée 9 instituts thématiques dans les domaines suivants :

- Neurosciences, sciences cognitives, neurologie, psychiatrie
- Cancer
- Immunologie, inflammation, infectiologie et microbiologie
- Physiopathologie, métabolisme et nutrition
- Santé publique
- Technologie pour la santé
- Bases moléculaires et structurales du vivant
- Biologie cellulaire, développement et évolution
- Génétique, génomique et bio-informatique

Son président-directeur général est Gilles Bloch, sa directrice générale déléguée est Claire Giry.

5.2 Le LIMICS

Le Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé (LIMICS) est une unité mixte de recherche interdisciplinaire en informatique et informatique médicale. Il est placé sous cotutelle de l'Inserm, de l'université Paris Sorbonne et de l'université Paris 13. Le laboratoire possède différentes localisations géographiques mais reste centré sur l'Île-de-France. Il développe des approches innovantes de traitement de l'information de santé sur le plan méthodologique et applicatif afin que les systèmes d'informations s'intègrent mieux dans les activités décisionnelles de soins et de recherche.

Cette unité est composée de 38 membres permanents parmi lesquels des chercheurs Inserm, des enseignants-chercheurs en informatique et des médecins et pharmaciens hospitalo-universitaires. Le LIMICS a pour ambition de se positionner comme une des principales équipes européennes en e-santé. Par ses nombreuses collaborations nationales et internationales, le LIMICS a su développer sa notoriété. Il est à l'origine de travaux de recherche en Intelligence Artificielle portant sur la représentation des connaissances en santé, leur formalisation dans des systèmes d'apprentissage et l'analyse décisionnelle à partir de données biomédicales.

Les connaissances et solutions technologiques qui émergent de travaux du laboratoire ont pour but d'être exploitées dans des recherches appliquées, translationnelles ou cliniques en partenariat avec d'autres laboratoires de recherche, des partenaires industriels et des structures de soins. Le LIMICS est engagé sur différentes thématiques de recherche telles que la représentation et formalisation des connaissances, l'intégration et analyse de données de santé, l'aide à la décision, l'évaluation des pratiques ainsi que l'étude de l'impact des solutions proposées notamment son impact en médecine factuelle. La directrice du laboratoire est Marie-Christine Jaulent, le directeur adjoint est Stefan Darmoni.

5.3 Problématique du stage

Le projet PsyHAMM est un projet ayant obtenu une accréditation de l'Agence Nationale de Recherche (ANR) et concerne les maladies psychiatriques. Il a démarré en février 2019 et prendra fin en août 2021.

Les maladies psychiatriques sont une priorité de santé publique. Elles représentent près d'environ 20% des dépenses de santé et si l'on additionne les coûts directs et indirects, elles coûtent près du double des maladies neurologiques et neurodégénératives. Au niveau européen, cela représente 432 milliards d'euros [Gustavsson et coll, 2011]. Environ 30% des patients ne répondent pas ou très peu aux traitements ; ce qui témoigne d'un besoin de développer de nouvelles stratégies thérapeutiques. Ces dernières années, l'existence de formes frontières entre les catégories diagnostiques classiques, la remise en question de certaines catégories ainsi que de nouvelles pistes physiopathologiques sont apparues.

La psychiatrie est un des domaines médicaux qui prescrit le plus de médicaments pour des indications différentes de celles pour lesquelles ils sont mis sur le marché, en particulier en milieu hospitalier. C'est ce que l'on appelle une utilisation hors de l'autorisation de mise sur le marché (hors AMM). On peut citer à titre d'exemple, l'utilisation d'agonistes dopaminergiques dans la dépression résistante ou l'utilisation du Lorazepam dans des présentations particulières et graves de troubles psychotiques comme la catatonie. Deux autres types fréquents d'hors AMM sont la prescription en dehors de la tranche d'âge prévue et la prescription en dehors de la posologie autorisée [Brauner et coll, 2016]. Les raisons de la prescription hors AMM sont diverses. Dans certains cas, l'objectif est de répondre aux besoins médicaux non couverts. C'est alors une prescription de bon sens chez des populations peu ou pas étudiées dans les essais mais chez lesquelles une extrapolation de l'AMM est raisonnable. Dans d'autres cas, l'objectif est de trouver une solution thérapeutique dans des situations cliniques difficiles, en cas d'inefficacité ou d'effet insuffisant des traitements disposant de l'AMM.

Pour un certain nombre de ces cas, l'ANSM s'est dotée de recommandations temporaires d'utilisation (RTU). Ce dispositif encadre médicalement une utilisation hors AMM lorsque qu'il existe un besoin thérapeutique et que le rapport bénéfice/risque du médicament est présumé favorable, notamment à partir de données scientifiques publiées d'efficacité et de tolérance. Toutefois dans la pratique clinique, une majorité des utilisations hors AMM des médicaments n'entre pas dans le cadre de ce dispositif. Étudier l'ensemble des cas de prescription hors AMM est important pour les analyser et mieux comprendre leur motivation.

L'Agence Régionale de Santé (ARS) demande des actions d'analyse de ces prescriptions mais ce type d'étude est rendu difficile en l'état puisque les données ne sont pas directement disponibles dans une base unique et des formats exploitables. Le Centre Hospitalier Sainte-Anne (CHSA) et certains autres centres sont concernés par cette problématique. Un des points de travail important du projet PsyHAMM est également de retrouver automatiquement ces prescriptions.

Les objectifs du projet se découpent en un objectif final médical et deux objectifs « informatiques » liés à la modélisation et au développement d'outils d'ingénierie des connaissances pour arriver à capturer et traiter les données. Plus précisément, l'objectif médical du projet est :

- La constitution d'échantillons de patients au sein des services de soin du CHSA permettant le repérage et l'analyse des utilisations hors AMM de médicaments.

Du point de vue de l'ingénierie des connaissances, le projet vise 2 objectifs :

- La constitution de ressources sémantiques et de deux ontologies ; une décrivant les médicaments et leurs AMM et une autre qui concerne les maladies tout en respectant des formats standards (ceux du Web sémantique).

Par ailleurs, au sein du LIMICS est développé HeTOP, un moteur de recherche de connaissances médicales qui contient les principales terminologies médicales alignées les unes aux autres. Il permettra de mettre à disposition du projet d'autres terminologies adaptées aux sujets d'intérêt, les médicaments et surtout les maladies non psychiatriques.

- Le développement d'un outil de récupération et structuration de données nécessaire au repérage et à l'analyse des prescriptions hors AMM. Les prescriptions médicamenteuses sont disponibles dans le logiciel de prescription « Génois » du CHSA et les informations du patient sont disponibles dans le Système d'Information Hospitalier (SIH) de l'hôpital, Cortexte. Ce format textuel nécessite de développer un outil spécifique.

Le LIMICS est parti des outils d'ingénierie des connaissances qu'il a développés depuis plusieurs années, à savoir l'ECMT (Extracteur de Concepts Multi-Terminologique [Sakji et coll, 2010]) et l'OnBaSAM (Ontology-Based Semantic Annotation Module [Cardoso et coll, 2016]). Fondés sur deux technologies différentes, ils permettront de mettre au point un outil performant d'annotation sémantique. Ensuite, il faudra extraire les informations sur les patients et les maladies à partir des comptes rendus d'hospitalisation et d'autres textes présents dans le dossier patient. L'outil d'annotation sera complété par la mise à disposition d'outils statistiques adaptés aux études spécifiques de l'analyse des prescriptions hors AMM.

Les résultats de ce travail de recherche permettront aux psychiatres et aux pharmaciens d'obtenir les données nécessaires pour étudier les prescriptions hors AMM ainsi que leur nature, leur fréquence et leur motivation. Par le passé, les découvertes de nouvelles catégories ont été faites à l'occasion d'observations fortuites comme pour les antidépresseurs, ou antipsychotiques par exemple. Ce travail sera une opportunité de suivre la mise en pratique des recommandations et une source pour identifier de nouveaux usages. La base de connaissances des médicaments, incluant leurs indications et doses maximales, restera ensuite disponible pour une utilisation future.

5.4 Objectifs du stage

Les objectifs initiaux de mon stage étaient l'alignement de référentiels bibliographiques, l'utilisation du serveur HeTOP et la contribution à sa mise à jour. Ces objectifs de stage ont évolué au fur et à mesure des avancées sur ces différents travaux.

5.4.1 Objectif principal

Mon objectif principal a été de proposer un référencement à jour de la littérature scientifique médicale afin d'aider les professionnels de santé dans leur information et prise de décision lors de la prescription hors AMM de nombreux médicaments. Ainsi, j'ai participé à l'alignement de référentiels bibliographiques à la fois pour le projet ANR « PsyHAMM » mais également pour d'autres projets hors du domaine psychiatrique. J'ai été initié à l'utilisation du serveur HeTOP et plus particulièrement à son versant axé sur le médicament et qui se nomme « HeTOP médicament ».

HeTOP est un serveur basé sur une classification ontologique et terminologique. Il permet une représentation des connaissances et des interactions entre différentes classes dans le champ des données médicales d'après la sémantique développée autour des notions qui lui sont intégrées. La figure 1 ci-dessous illustre l'ensemble des notions autour de chaque médicament référencé sur HeTOP ; chacune de ces notions possède une sémantique permettant la classification de l'ensemble des médicaments.



Figure 1: modèle sémantique du médicament en France

Dans le cadre de ce travail de référencement, j'ai été encadré par Catherine Letord, pharmacienne rattachée au Centre Hospitalo-Universitaire (CHU) de Rouen, membre du LIMICS et de l'Inserm U11 42 qui contribue au projet PsyHAMM. Elle m'a apporté l'ensemble des références bibliographiques utilisées au début de mon stage et j'ai ainsi traité un grand nombre de celles-ci afin de les intégrer à HeTOP. Par la suite, j'ai fait mes propres recherches afin de continuer les travaux qui avaient été démarrés avant mon arrivée dans le projet. Jean Charlet et Catherine Letord m'ont encadré au cours de ces recherches afin de valider leur contenu dans le cadre du projet PsyHAMM.

5.4.2 Objectifs secondaires

Au cours de mon travail sur HeTOP, le Professeur Darmoni rédigait un article à son propos. Il m'a alors chargé de le relire. J'ai donc participé à la correction et l'ajout de certains éléments de l'article. Par la suite, le Professeur Darmoni a souhaité que je participe à la rédaction d'un article scientifique concernant HeTOP dans le cadre d'une évaluation qualitative du serveur. Jean Charlet, mon maître de stage, et le professeur Stefan Darmoni m'ont encadré au cours de la rédaction de cet article.

5.5 Réalisation des objectifs

Les objectifs de ce stage m'ont permis d'aborder différents aspects des travaux du LIMICS pendant ces six mois.

En premier lieu, j'ai réalisé l'alignement de référentiels en maladies psychiatriques dans le cadre du projet PsyHAMM et également non psychiatriques pour des prescriptions hors AMM. J'ai pu renseigner au mieux le serveur HeTOP avec les références bibliographiques issues des travaux de Catherine Letord auxquels j'ai joint mes recherches. J'ai ainsi consulté de nombreux articles sur Pubmed se trouvant dans la liste des annexes de ce rapport. J'ai rendu compte de mes recherches à Catherine Letord et Jean Charlet par des tableaux Excel.

DCI	Nom de spécialité	Adulte/Enfant	Indication hors AMM	Références
Citalopram	Seropram	Adulte	Alzheimer	Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422. Review. PubMed PMID: 26159445.

Tableau 1: exemple de ligne de tableau de compte-rendu des recherches hors AMM en psychiatrie

Ces recherches ont concerné les indications psychiatriques hors AMM du projet PsyHAMM, toujours sous la supervision de Catherine Letord. Au-delà de ces travaux de recherche, nous avons renseigné les indications hors AMM données par les équipes de médecins et pharmaciens de l'hôpital Saint-Anne qui sont partenaires de ce projet. J'ai ainsi travaillé afin d'identifier la littérature à la fois la plus pertinente et la plus récente pour renseigner « HeTOP médicament » (interface du serveur HeTOP consacrée spécifiquement aux informations sur les médicaments). J'ai fait part de mes différentes observations à l'équipe en charge de la base de données quand cela semblait nécessaire afin de contribuer à l'améliorer. C'est ainsi que j'ai pu renseigner la zone « Commentaires » de l'onglet « Indications hors AMM » des différents médicaments étudiés. La figure 2 ci-dessous présente une capture d'écran de « HeTOP médicament » lors de l'affichage d'une recherche de spécialité pharmaceutique.



Figure 2: exemple d'informations sur un médicament par « HeTOP médicament »

Lorsque l'on s'intéresse à cet exemple, on constate 8 indications hors AMM. En cliquant sur une indication, on obtient la liste des médicaments prescrits. HeTOP propose des informations complémentaires à cette recherche. La figure 3 ci-dessous donne une illustration

de la recherche de « Prozac » sur HeTOP. Dans l'onglet « Relations », on trouve les indications de l'AMM du Prozac et les indications hors AMM.



Figure 3: exemple d'informations sur un médicament avec « HeTOP »

La figure 4 donne un aperçu de la fenêtre des « Motif(s) de prescription hors AMM ». On y retrouve différentes indications pour lesquelles on obtient des informations en cliquant. On aperçoit également un encadré portant une bulle bleue à côté de chaque ligne. Cet encadré est la section « Commentaires » et renvoie à une fenêtre dans laquelle sont renseignées les recherches que j'ai effectuées au cours de mon stage.



Figure 4: exemple qui montre les motif(s) de prescription hors AMM du Prozac

La figure 5 montre les informations présentes dans l'onglet « Commentaires ». Cet onglet a été adapté au cours de mon stage afin de pouvoir contenir le maximum de documentation à propos des indications hors AMM pour les différents médicaments.



Figure 5: présentation de la section « Commentaires » de l'onglet « Motif(s) de prescription hors AMM »

Dans un deuxième temps, j'ai mené une évaluation qualitative sur le serveur HeTOP à la demande du Professeur Darmoni. Le but de cette évaluation était de comprendre comment HeTOP est perçu par les utilisateurs. J'ai présenté la base de données HeTOP et mes travaux devant différents membres du LIMICS, tous hors d'un cursus universitaire de santé. J'ai recueilli leurs évaluations et je me suis alors tourné vers des étudiants en pharmacie. Nous avons fait le choix de prendre des étudiants de 5e année de pharmacie dans les filières « industrie et recherche », « officine » et « internat » afin d'obtenir la perception de cet outil par des futurs professionnels de santé. Cette évaluation comporte 3 échelles de Likert et un verbatim.



Filière :

Évaluation HeTOP médicaments :

- Évaluation quantitative

Intérêt sur les compétences

0 ——— 10

Intérêt pédagogique

0 ——— 10

Simplicité d'affichage des résultats

0 ——— 10

- Avis sur HeTOP médicaments en comparaison des bases de données sur le médicament (Vidal, Thériaque, CRAT, etc...)

Points positifs	Points Négatifs

- Quel est, selon vous, l'intérêt de cet outil ?

Figure 6: fiche d'évaluation qualitative de HeTOP

Après recueil des réponses en quantité suffisante, nous analyserons de manière statistique les notes obtenues (moyenne, écart-type, test du Khi-deux) et les verbatims. Nous mettrons en évidence la corrélation de certains paramètres et dégagerons les premières conclusions concernant l'usage d'HeTOP par les évaluateurs. Ci-dessous, le tableau donne un exemple de recueil de résultats de l'évaluation qualitative. En obtenant des cohortes suffisamment élevées, nous aurons assez de puissance pour effectuer nos tests statistiques.

N° participant	Intérêt sur les compétences	Intérêt pédagogique	Simplicité d'affichage	Sous-groupe
1	8.4	8.9	7.7	5A I&R
2	8.8	10	6.1	5A Officine

Tableau 2: exemple de recueil des résultats de l'évaluation d'HeTOP

Voici une présentation des premiers résultats obtenus avec la cohorte du groupe d'étudiants en pharmacie pour n=20.

	Intérêt sur les compétences	Intérêt pédagogique	Simplicité d'affichage	Sous-groupe
5A I&R	X =7.68 ± 0.97 (σ)	X= 8.38 ± 0.75 (σ)	X= 7.44 ± 1.44 (σ)	10
5A Officine	X=7.95 ± 1.55(σ)	X= 8.75 ± 1.30 (σ)	X= 7.53 ± 1.64 (σ)	4
5A Internat	X= 7.33 ± 0.95 (σ)	X= 6.77 ± 1.05 (σ)	X= 5.78 ± 1.59 (σ)	6

Tableau 3: résultats de l'évaluation qualitative pour une cohorte de n=20 participants

Nous sommes actuellement en cours de rédaction de l'article scientifique en anglais où le professeur Darmoni et Jean Charlet m'apportent leur encadrement précieux. Cet exercice nouveau me permet de me confronter à l'exigence du monde scientifique et est un moyen d'exposer et mettre en valeur le travail que j'ai réalisé au cours de ce stage au LIMICS. Au moment de l'écriture de ce rapport, nous sommes toujours en cours de recueil des résultats et en rédaction de l'article.

Enfin, dans un dernier temps, Jean Charlet m'a formé à la discipline de l'ontologie sur le logiciel Protégé. C'est au cours d'une journée de formation qu'il a donnée au laboratoire que j'ai pu bénéficier des enseignements qu'il dispense habituellement à l'université. J'ai appris à créer une ontologie, l'enrichir, la modifier et obtenir des résultats à partir de celle-ci. Suite à cette formation, j'ai manipulé l'ontologie réalisée par Sonia Cardoso et Jean Charlet dans le cadre de leurs travaux sur la sclérose latérale amyotrophique. J'ai participé à l'alignement des classes et des concepts ainsi que la traduction de certains concepts lors de l'enrichissement de l'ontologie.

5.6 Conclusion

Sur le plan professionnel, ce stage m'a permis d'intégrer le monde de la recherche dans un organisme public. Je me suis imprégné de l'ambiance du laboratoire au cours de ces 6 mois et on m'y a transmis l'importance d'avoir une vision critique. Le LIMICS mène et collabore sur de nombreux projets. J'ai ainsi bénéficié d'une ouverture sur les avancées techniques dans le domaine médical, en particulier sur les projets liants médical et ingénierie. L'essentiel de mon travail aura été associé de façon directe ou indirecte au serveur HeTOP, projet du LIMICS. J'ai pu réaliser à quel point cet outil est bien documenté et tend à représenter de façon optimale les connaissances dans le domaine du médical qui est en constante avancée. En représentant les connaissances et en cherchant à être le plus à jour possible sur la littérature médicale, HeTOP est un outil potentiel pour dégager les médicaments d'intérêt dans le cadre des prescriptions hors AMM. Il pourrait potentiellement permettre de faire réviser leur situation, et impacter alors le coût de la prise en charge du patient dans un but d'amélioration de l'efficience du système de santé français. J'ai suivi avec beaucoup d'intérêt la formation sur l'ontologie dispensée par mon maître de stage Jean Charlet. Ce fut une opportunité d'être initié à une méthode d'intérêt dans le domaine des connaissances en santé.

Sur le plan personnel, ce stage m'a permis de découvrir de façon plus concrète le monde de la recherche dans le domaine médical. J'ai été sensibilisé aux nombreuses opportunités qu'il contient, à l'aspect pluridisciplinaire du paysage de la recherche médicale en France. J'y ai beaucoup apprécié l'ambiance de travail en grande autonomie, la confiance au sein de l'équipe et la convivialité. J'ai travaillé sur les différents objectifs de mon stage et je les ai atteints grâce à une équipe à l'écoute et dont j'ai appris tant sur le plan technique qu'humain. Mes encadrants, les chercheurs du laboratoire et mes collègues ont été des rencontres enrichissantes dans le cadre de mon développement personnel.

En conclusion, ma participation au projet ANR « PsyHAMM » fut enrichissante à tous les niveaux. Ayant été sensibilisé au contexte de la psychiatrie en France, j'ai pris du recul pour comprendre les enjeux de ce projet. L'importance des dépenses de santé en France dans le domaine de la psychiatrie et le nombre de prescriptions hors AMM ainsi que leur prise en charge par la Sécurité Sociale sont des éléments qui donnent à penser qu'HeTOP possède un rôle important à jouer.

Ce stage constitue également une bonne entrée en matière pour le master 2 de pharmaco-épidémiologie auquel je suis inscris à Sorbonne Université pour la rentrée 2019. En effet, je vais être formé à l'évaluation d'indicateurs autour du médicament en vie réelle dans une perspective d'évaluation de l'efficience du système de santé en France. Ce master 2 me formera à devenir acteur, je l'espère, autour de ces enjeux lors de ma carrière professionnelle.

6 Références bibliographiques

R. Hoff, A.W. Braam. Off-labelmedicatie in de crisisdienst: een praktijkevaluatie. tijdschrift voor psychiatrie 55(2013)4, 233-245]

Lenk C, Koch P, Zappel H, Wiesemann C. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr. 2009 Dec;168(12):1473-8. doi: 10.1007/s00431-009-0956-6. Epub 2009 Mar 11. PubMed PMID: 19277709; PubMed Central PMCID: PMC2772947.

Furey K, Wilkins K. Prescribing "Off-Label": What Should a Physician Disclose? AMA J Ethics. 2016 Jun 1;18(6):587-93. doi: 10.1001/journalofethics.2016.18.6.ecas3-1606. PubMed PMID: 27322992.

Fairman KA, Curtiss FR. Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm. 2010 Oct;16(8):629-39. PubMed PMID: 20866167.

Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177-84. doi: 10.1002/pds.2082. Epub 2011 Jan 6. PubMed PMID: 21254289; PubMed Central PMCID: PMC3069498.

Kearns MA, Hawley KM. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists. J Psychiatr Pract. 2014 Nov;20(6):438-47. doi: 10.1097/01.pra.0000456592.20622.45. PubMed PMID: 25406048; PubMed Central PMCID: PMC6208135.

Driessen J, Baik SH, Zhang Y. Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012. Psychiatr Serv. 2016 Aug 1;67(8):898-903. doi: 10.1176/appi.ps.201500316. Epub 2016 Apr 15. PubMed PMID: 27079991; PubMed Central PMCID: PMC4969167.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053129.

Sakji S, Gicquel Q, Pereira S, Kergourlay I, Proux D, Darmoni S, Metzger MH. Evaluation of a French medical multi-terminology indexer for the manual annotation of natural language medical reports of healthcare-associated infections. Stud Health Technol Inform. 2010; 160 (Pt 1):252-6.

Gustavsson A. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Oct ; 21(10) : 718-79.

Cardoso S., Aimé X., Jaulent L. F. M. M. M.-C., Grabli D., Meininger V. et Charlet J. Les ontologies pour aider à comprendre les parcours de santé dans le cadre des maladies neurodégénératives. In 2e Atelier IA et santé associé à la conférence IC2016, Montpellier, France, juin 2016.

Braüner JV, Johansen LM, Roesbjerg T, Pagsberg AK. Off-Label Prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry. J Clin Psychopharmacol. 2016 Oct; 36(5):500-7.

J. Grosjean, C. Letord, J. Charlet, X. Aimé, L. Danès, J. Rio, SJ. Darmoni, C. Duclos. Un modèle sémantique d'identification du médicament en France. Atelier IA & Santé (2019). https://ia-sante-2019.sciencesconf.org (*Illustration en page suivante)*

HeTOP : https://www.hetop.eu/hetop/

HeTOP médicament : https://www.hetop.eu/hetop/drugs/

Cours de formation à l’ontologie :

https://www.researchgate.net/publication/317936945_Cours_Ontologies_terminologie_Web_semantique

https://www.researchgate.net/publication/318208041_Creation_d'une_ontologie_en_OWL_avec_Protege_45

Un modèle sémantique d'identification du médicament en France

J. Grosjean[1,2], C. Letord[1,2], J. Charlet[2,3], X. Aimé[2], L. Danès[2], J. Rio[1], I. Zana[2], SJ. Darmoni[1,2], C. Duclos[2,3]

[1] Department of Biomedical Informatics, Rouen University Hospital, 76031 Rouen Cedex, France;
{Julien.Grosjean,Catherine.Letord,Julien.Rio,Stefan.Darmoni}@chu-rouen.fr
[2] Sorbonne Université, INSERM, Université Paris 13, LIMICS, Paris, France;
xavier.aime@cogsonomy.fr,loane.danes@agroparistech.fr,ilan.zana26@gmail.com
[3] Assistance Publique-Hôpitaux de Paris, DRCI, Paris, France
{Jean.Charlet,Catherine.Duclos}@aphp.fr}

Résumé : il n'existe pas de standard universellement accepté pour nommer les médicaments. L'identification du médicament a fait l'objet de nombreux travaux de normalisation. Notre objectif est de définir un modèle formel du médicament en français pour lier les différentes entités manipulables autour du médicament. Ce modèle formel vise un double sous-objectif : (a) créer et instancier une ontologie formelle du médicament ; (b) créer une terminologie du médicament, intégrable dans un serveur de terminologies. À terme, ces ressources seront des outils puissants pour, notamment, supporter la recherche d'information dans des bases de médicaments ou des entrepôts de données. Ils seront mis librement à disposition de la communauté.

Mots-clés : ontologie ; terminologie ; serveur de terminologie ; modèle formel ; médicament.

1 Introduction

Bien que le médicament soit fini, identifiable, il n'existe pas de standard universellement accepté pour le représenter (Cimino 1999). Selon le point de vue auquel on se place, on peut le définir à un niveau moléculaire (comme une substance active), à un niveau clinique (comme un produit capable de traiter une pathologie) ou encore à un niveau physique (comme une présentation destinée à satisfaire la prescription et délivrable au patient). L'identification du médicament peut donc se concevoir à divers niveaux ayant des degrés d'abstraction plus ou moins grands (Sperzel 1998) (i) une présentation, un produit manufacturé ou un ingrédient correspondent à des objets physiques, (ii) un produit clinique ou une fraction thérapeutique sont de pures abstractions.

L'identification du médicament a fait l'objet de nombreux travaux de normalisation dont les plus récents définissent l'identification du produit médicinal et du produit pharmaceutique (ISO 11615, ISO 11616, ISO 20443, ISO 11238, ISO 11239, ISO 11240) afin de rendre le partage international de l'information sur le médicament possible. Le référentiel résultant sera disponible en 2020 au niveau de l'agence européenne du médicament (EMA). D'autres modèles ont été adoptés pour représenter le médicament dans les bases de données sur le médicament (Broverman 1998, DMD[1]), ou pour servir de pivot entre des bases des données sur le médicament (RxNorm[2]). Dans ces modèles, se retrouve cette dualité entre virtuel et réalité et les relations de composition entre ingrédients actifs, dosages et formes.

[1] https://apps.nhsbsa.nhs.uk/DMDBrowser/DMDBrowser.do
[2] https://www.nlm.nih.gov/research/umls/rxnorm

7 Liste des annexes et annexes

7.1 Articles concernant le hors AMM dans les domaines non psychiatriques

Bayraktar F, Hamulu F, Ozgen AG, Yilmaz C, Tüzün M, Kabalak T. Acarbose treatment in obesity: a controlled study. Eat Weight Disord. 1998 Mar;3(1):46-9. PubMed PMID: 11234255.

Nakhaee A, Sanjari M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. J Res Med Sci. 2013 May;18(5):391-4. PubMed PMID: 24174943; PubMed Central PMCID: PMC3810572.

Penna IA, Canella PR, Reis RM, Silva de Sá MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod. 2005 Sep;20(9):2396-401. Epub 2005 Jul 8. PubMed PMID: 16006454.

Siraj ES. Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med. 2003 Aug;70(8):702-4. Review. PubMed PMID: 12959396.

Hauner H, Petzinna D, Sommerauer B, Toplak H. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab. 2001 Dec;3(6):423-7. PubMed PMID: 11903414.

Berger M. Pharmacological treatment of obesity: digestion and absorption inhibitors-clinical perspective. Am J Clin Nutr. 1992 Jan;55(1 Suppl):318S-319S. doi: 10.1093/ajcn/55.1.318s. Review. PubMed PMID: 1728847.

De Cunto A, Barbi E, Minen F, Ventura A. Safety and efficacy of high-dose acarbose treatment for dumping syndrome. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):113-4. doi: 10.1097/MPG.0b013e31820ae6d1. PubMed PMID: 21694549.

Vahedi K, Taupin P, Djomby R, El-Amrani M, Lutz G, Filipetti V, Landais P, Massiou H, Bousser MG; DIAMIG investigators. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol. 2002 Feb;249(2):206-11. PubMed PMID: 11985388.

Eur Arch Otorhinolaryngol. 2016 Oct;273(10):2947-51. doi: 10.1007/s00405-015-3874-4. Epub 2016 Jan 4. Acetazolamide in vestibular migraine prophylaxis: a retrospective study. Çelebisoy N1, Gökçay F2, Karahan C3, Bilgen C3, Kirazlı T3, Karapolat H4, Köse T5. PMID: 26728486.

Rodriguez-Zuniga M, Torres N, Garcia-Perdomo H. Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. An Bras Dermatol. 2018 Sep-Oct;93(5):686-695. doi: 10.1590/abd1806-4841.20187252. Review. PubMed PMID: 30156618; PubMed Central PMCID: PMC6106661.

Chang HC, Sung CW, Lin MH. The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis. J Dermatolog Treat. 2018 Sep 4:1-6. doi: 10.1080/09546634.2018.1508820. [Epub ahead of print] PubMed PMID: 30109959.

Singh S; Anurag, Tiwary NK. Acyclovir is not effective in pityriasis rosea: Results of a randomized, triple-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):505-9. doi:10.4103/0378-6323.182791. PubMed PMID: 27212277.

Das A, Sil A, Das NK, Roy K, Das AK, Bandyopadhyay D. Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Indian Dermatol Online J. 2015 May-Jun;6(3):181-4. doi:10.4103/2229-5178.156389. PubMed PMID: 26009712; PubMed Central PMCID: PMC4439746.

Drago F, Ciccarese G, Rebora A, Parodi A. The efficacy of macrolides and acyclovir in pityriasis rosea. Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):56. doi: 10.4103/0378-6323.148572. PubMed PMID: 25566900.

Ganguly S. A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea. J Clin Diagn Res. 2014 May;8(5): YC01-4. doi: 10.7860/JCDR/2014/8140.4360. Epub 2014 May 15. PubMed PMID: 24995231; PubMed Central PMCID: PMC4080052.

Amatya A, Rajouria EA, Karn DK. Comparative study of effectiveness of oral acyclovir with oral

erythromycin in the treatment of Pityriasis rosea. Kathmandu Univ Med J (KUMJ). 2012 Jan-Mar;10(37):57-61. PubMed PMID: 22971864.

Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients. J Eur Acad Dermatol Venereol. 2011 Jan;25(1):24-6. doi: 10.1111/j.1468-3083.2010.03676.x. PubMed PMID: 20477925.

Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006 Jan;54(1):82-5. PubMed PMID: 16384760.

Castanedo-Cazares JP, Lepe V, Moncada B. Antivirals for pityriasis rosae. Photodermatol Photoimmunol Photomed. 2004 Apr;20(2):110. PubMed PMID: 15030598.

Chuh A. Narrow band UVB phototherapy and oral acyclovir for pityriasis rosea. Photodermatol Photoimmunol Photomed. 2004 Feb;20(1):64-5. PubMed PMID: 14738537.

Alam A, Bopardikar A, Au S, Barrett J, Callum J, Kiss A, Choi S. Protocol for a pilot, randomised, double-blinded, placebo-controlled trial of prophylactic use of tranexamic acid for preventing postpartum haemorrhage (TAPPH-1). BMJ Open. 2017 Oct 11;7(10): e018586. doi: 10.1136/bmjopen-2017-018586. PubMed PMID: 29025850; PubMed Central PMCID: PMC5652619.

Ahmadzia HK, Phillips JM, Katler QS, James AH. Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. Obstet Gynecol Surv. 2018 Oct;73(10):587-594. doi: 10.1097/OGX.0000000000000597. Review. PubMed PMID: 30379320.

Chassard D, Bouvet L. Administration of tranexamic acid to reduce maternal mortality related to postpartum haemorrhage: comments on the WOMAN trial. Int J Obstet Anesth. 2018 Feb; 33: 89-90. doi: 10.1016/j.ijoa.2017.07.010. Epub 2017 Jul 25. PubMed PMID: 28899732.

Pacheco LD, Hankins GDV, Saad AF, Costantine MM, Chiossi G, Saade GR. Tranexamic Acid for the Management of Obstetric Hemorrhage. Obstet Gynecol. 2017 Oct;130(4):765-769. doi: 10.1097/AOG.0000000000002253. PubMed PMID: 28885402.

WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26. Erratum in: Lancet. 2017 May 27;389(10084):2104. PubMed PMID: 28456509; PubMed Central PMCID: PMC5446563.

Sentilhes L, Brun S, Madar H, Merlot B, Deneux-Tharaux C. Re: Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials: A very welcome publication. BJOG. 2017 May;124(6):982. doi: 10.1111/1471-0528.14421. PubMed PMID: 28429442.

Li C, Gong Y, Dong L, Xie B, Dai Z. Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention? : A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jan;96(1):e5653. doi: 10.1097/MD.0000000000005653. Review. PubMed PMID: 28072700; PubMed Central PMCID: PMC5228660.

Sentilhes L, Goffinet F, Deneux-Tharaux C. Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage. Am J Kidney Dis. 2017 Jan;69(1):160. doi: 10.1053/j.ajkd.2016.02.059. PubMed PMID: 28007187.

Ker K, Shakur H, Roberts I. Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials. BJOG. 2016 Oct;123(11):1745-52. doi: 10.1111/1471-0528.14267. Epub 2016 Aug 24. Review. PubMed PMID: 27558956.

Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015 Jun 16;(6):CD007872. doi: 10.1002/14651858.CD007872.pub3. Review. PubMed PMID: 26079202.

Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, Goffinet F, Deneux-Tharaux C. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth. 2015 Apr;114(4):576-

87. doi: 10.1093/bja/aeu448. Epub 2015 Jan 8. Review. PubMed PMID: 25571934.

Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014 Jul;171(1):170-4. doi: 10.1111/bjd.12884. Epub 2014 Apr 29. PubMed PMID: 24506875.

Guenther LC, Kunynetz R, Lynde CW, Sibbald RG, Toole J, Vender R, Zip C. Acitretin Use in Dermatology. J Cutan Med Surg. 2017 Nov/Dec;21(3_suppl):2S-12S. doi: 10.1177/1203475417733414. Epub 2017 Sep 27. Review. PubMed PMID: 28952335.

Tan MG, Shear NH, Walsh S, Alhusayen R. Acitretin. J Cutan Med Surg. 2017 Jan/Feb;21(1):48-53. doi: 10.1177/1203475416659858. Epub 2016 Jul 19. PubMed PMID: 27432818.

Deckers IE, Prens EP. An Update on Medical Treatment Options for Hidradenitis Suppurativa. Drugs. 2016 Feb;76(2):215-29. doi: 10.1007/s40265-015-0516-5. Review. PubMed PMID: 26659474.

van der Zee HH, Gulliver WP. Medical Treatments of Hidradenitis Suppurativa: More Options, Less Evidence. Dermatol Clin. 2016 Jan;34(1):91-6. doi: 10.1016/j.det.2015.08.006. Review. PubMed PMID: 26617362.

Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with systematic review. Br J Dermatol. 2013 Feb;168(2):243-52. doi: 10.1111/bjd.12104. Review. PubMed PMID: 23106519.

Nazary M, van der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol. 2011 Dec 15;672(1-3):1-8. doi: 10.1016/j.ejphar.2011.08.047. Epub 2011 Sep 14. Review. PubMed PMID: 21930119.

Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011 Jan;164(1):170-5. doi: 10.1111/j.1365-2133.2010.10071.x. PubMed PMID: 20874789.

Scheman AJ. Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report. Cutis. 2002 Apr;69(4):287-8. PubMed PMID: 12080949.

Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988 Aug;19(2 Pt 1):355-6. PubMed PMID: 2971689.

Poveda-Roda R, Bagan JV, Jiménez-Soriano Y, Díaz-Fernández JM, Gavaldá-Esteve C. Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study. Med Oral Patol Oral Cir Bucal. 2010 Jan 1;15(1): e3-9. PubMed PMID: 19680182.

Gaeta GM, Gombos F, Femiano F, Battista C, Minghetti P, Montanari L, Satriano RA, Argenziano G. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. J Eur Acad Dermatol Venereol. 2000 Nov;14(6):473-8. PubMed PMID: 11444269.

Laskaris G. How to treat oral leucoplakia. J Eur Acad Dermatol Venereol. 2000 Nov;14(6):446-7. PubMed PMID: 11444265.

Bousema MT, Romppanen U, Geiger JM, Baudin M, Vähä-Eskeli K, Vartiainen J, Vuopala S. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J Am Acad Dermatol. 1994 Feb;30(2 Pt 1):225-31. PubMed PMID: 8288782.

Formiga Ade A, Torres Ide S, Rocha Bde O, Silva AO, Follador I, Rêgo VR, de Oliveira Mde F. Disseminated extragenital lichen sclerosus et atrophicus treated with acitretin. Skinmed. 2014 Jan-Feb;12(1):62-3. PubMed PMID: 24720089.

Ioannides D, Lazaridou E, Apalla Z, Sotiriou E, Gregoriou S, Rigopoulos D. Acitretin for severe lichen sclerosus of male genitalia: a randomized, placebo controlled study. J Urol. 2010 Apr;183(4):1395-9. doi: 10.1016/j.juro.2009.12.057. Epub 2010 Feb 19. PubMed PMID: 20171665.

Basak PY, Basak K. Lichen sclerosus et atrophicus of the scalp: satisfactory response to acitretin. J Eur Acad Dermatol Venereol. 2002 Mar;16(2):183-5. PubMed PMID: 12046836.

Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol. 1988 Jun;124(6):897-902. PubMed PMID: 2967674.

Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992 Nov;127(5):513-8. PubMed PMID: 1467292.

Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen's disease with acitretin. Int J Dermatol. 2002 Feb;41(2):84-7. PubMed PMID: 11982642.

Khandpur S, Sharma VK. Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. J Dermatol. 2003 Oct;30(10):730-4. PubMed PMID: 14684956.

Newland K, Marshman G. Success treatment of post-irradiation morphoea with acitretin and narrowband UVB. Australas J Dermatol. 2012 May;53(2):136-8. doi: 10.1111/j.1440-0960.2011.00864.x. Epub 2012 Feb 16. PubMed PMID: 22571564.

Almutawa F, Thusaringam T, Watters K, Gayden T, Jabado N, Sasseville D. Pachyonychia Congenita (K16) with Unusual Features and Good Response to Acitretin. Case Rep Dermatol. 2015 Aug 19;7(2):220-6. doi: 10.1159/000438920. eCollection 2015 May-Aug. PubMed PMID: 26464567; PubMed Central PMCID: PMC4592507.

Gruber R, Edlinger M, Kaspar RL, Hansen CD, Leachman S, Milstone LM, Smith FJ, Sidoroff A, Fritsch PO, Schmuth M. An appraisal of oral retinoids in the treatment of pachyonychia congenita. J Am Acad Dermatol. 2012 Jun; 66(6): e193-9. doi: 10.1016/j.jaad.2011.02.003. Epub 2011 May 24. PubMed PMID: 21601946.

Lucker GP, Steijlen PM. Pachyonychia congenita tarda. Clin Exp Dermatol. 1995 May;20(3):226-9. PubMed PMID: 7671418.

Mota F, Carvalho S, Sanches M, Selores M. Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin. Acta Dermatovenerol Alp Pannonica Adriat. 2016;25(1):15-7. PubMed PMID: 27014774.

Mavrogianni P, Fallidas E, Nicolaidou E, Villias K, Stefanaki I, Katsambas A, Lira T, Apostolopoulos P, Androne I, Rouvas G, Tsibouris P, Alexandrakis G. Therapeutic combination of radiofrequency surgical dissection and oral acitretin in the management of perianal Buschke-Lowenstein tumour: a case report. Int J STD AIDS. 2012 May;23(5):362-4. doi: 10.1258/ijsa.2011.011301. PubMed PMID: 22648893.

El-Khayat RH, Hague JS. Use of acitretin in the treatment of resistant viral warts. J Dermatolog Treat. 2011 Aug; 22(4): 194-6. doi: 10.3109/09546631003674339. Epub 2010 May 5. PubMed PMID: 20443666.

Yiu ZZ, Madan V, Griffiths CE. Acne conglobata and adalimumab: use of tumour necrosis factor-α antagonists in treatment-resistant acne conglobata, and review of the literature. Clin Exp Dermatol. 2015 Jun;40(4):383-6. doi: 10.1111/ced.12540. Epub 2014 Dec 26. Review. PubMed PMID: 25545016.

Sand FL, Thomsen SF. Adalimumab for the treatment of refractory acne conglobata. JAMA Dermatol. 2013 Nov;149(11):1306-7. doi: 10.1001/jamadermatol.2013.6678. PubMed PMID: 24048280.

Altinyazar HC, Koca R, Tekin NS, Eştürk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005 Mar;44(3):252-5. PubMed PMID: 15807740.

Parodi A, Drago F, Paolino S, Cozzani E, Gallo R. [Treatment of rosacea]. Ann Dermatol Venereol. 2011 Sep;138 Suppl 2: S158-62. doi: 10.1016/S0151-9638(11)70082-5. French. PubMed PMID: 21907876.

Lehmann P. [Rosacea. Clinical features, pathogenesis and therapy]. Hautarzt. 2005 Sep;56(9):871-85; quiz 886-7. Review. German. PubMed PMID: 16133636.

Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011 Feb;96(2):355-64. doi:10.1210/jc.2010-0636. Epub 2010 Nov 24. PubMed PMID: 21106710.

Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. Endocr Pract. 2018 Feb;24(2):179-188. doi: 10.4158/EP171910.OR. PubMed PMID: 29466057.

Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M. THE CLINICAL CHARACTERISTICS AND

EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA. Endocr Pract. 2016 Nov;22(11):1267-1276. Epub 2016 Aug 2. PubMed PMID: 27482615.

Lv F, Liu Y, Xu X, Wang J, Ma D, Jiang Y, Wang O, Xia W, Xing X, Yu W, Li M. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA. Endocr Pract. 2016 Dec;22(12):1369-1376. Epub 2016 Aug 2. PubMed PMID: 27482608.

Wei SS, Cai QX, Qiu WJ, Zhao L, Ye J, Wang XL, Chen Q, Gu XF. [Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta]. Zhonghua Yi Xue Za Zhi. 2012 Jan 31;92(4):246-9. Chinese. PubMed PMID: 22490796.

Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr. 2008 Feb;45(2):105-9. PubMed PMID: 18310788.

Shah I, Johari A. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective. Ann Trop Paediatr. 2007 Mar;27(1):39-43. PubMed PMID: 17469731.

Madenci E, Yilmaz K, Yilmaz M, Coskun Y. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol. 2006 Apr;12(2):53-6. PubMed PMID: 16601536

Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006 Feb;21(2):300-6. Epub 2005 Oct 24. PubMed PMID: 16418786.

Unal E, Abaci A, Bober E, Buyukgebiz A. Oral alendronate in osteogenesis imperfecta. Indian Pediatr. 2005 Nov;42(11):1158-60. PubMed PMID: 16340059.

Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop. 2005 Sep-Oct;25(5):607-12. PubMed PMID: 16199940.

Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res. 2013 Feb;28(2):395-403. doi: 10.1002/jbmr.1755. PubMed PMID: 22991163.

Kapser C, Herzinger T, Ruzicka T, Flaig M, Molin S. Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):783-8. doi: 10.1111/jdv.12684. Epub 2014 Aug 29.

Motschenbacher S, Buder K, Goebeler M, Kerstan A. Combined oral alitretinoin and narrowband UVB treatment of cutaneous T cell lymphoma: favourable response after multiple ineffective systemic therapies. Eur J Dermatol. 2012 Nov-Dec;22(6):803-4. doi: 10.1684/ejd.2012.1857. PubMed PMID: 23107626.

Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J. Am Acad Dermatol. 2012 Sep; 67(3): e123-6. doi: 10.1016/j.jaad.2011.10.030.

Letulé V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol. 2013 Jul;38(5):523-5. doi: 10.1111/ced.12078

Shreberk-Hassidim R, Sheffer S, Horev L, Zlotogorski A, Ramot Y. Successful treatment of refractory Darier disease with alitretinoin with a follow up of over a year: a case report. Dermatol Ther. 2016 Jul;29(4):222-3. doi: 10.1111/dth.12366. Epub 2016 Jun 6. PubMed PMID: 27272615.

Balestri R, Patrizi A, Bardazzi F. Alitretinoin and Darier disease: "All that glisters is not gold". J Am Acad Dermatol. 2015 Feb;72(2):363-4. doi: 10.1016/j.jaad.2014.09.054. PubMed PMID: 25592350.

Zamiri M, Munro CS. Successful treatment with oral alitretinoin in women of childbearing potential with Darier's disease. Br J Dermatol. 2013 Sep;169(3):709-10. doi: 10.1111/bjd.12348. PubMed PMID: 23551220.

Barnstedt SE. [Successful treatment of Darier disease with oral alitretinoin]. Hautarzt. 2012 Feb;63(2):139-41. doi: 10.1007/s00105-011-2207-9. German. PubMed PMID: 21761212.

Miernik B, Schmidt V, Technau-Hafsi K, Kern JS, Meiss F. Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach. Clin Exp Dermatol. 2015 Jun;40(4):445-7. doi: 10.1111/ced.12516. Epub 2014 Dec 5

Park J, Kwon O, Park K, Chung H. Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation. Clin Exp Dermatol. 2017 Apr;42(3):341-342. doi: 10.1111/ced.13046. Epub 2017 Feb 16. PubMed PMID: 28211143.

Coors EA, von den Driesch P. Treatment of 2 patients with mycosis fungoides with alitretinoin. J Am Acad Dermatol. 2012 Dec;67(6): e265-7. doi: 10.1016/j.jaad.2012.05.011. PubMed PMID: 23158629.

Molin S, Ruzicka T. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndrome. Br J Dermatol. 2009 Dec;161(6):1420-2. doi: 10.1111/j.1365-2133.2009.09475.x. Epub 2009 Sep 28.

Molin S, Ruzicka T. Treatment of refractory pityriasis rubra pilaris with oral alitretinoin: case report. Br J Dermatol. 2010 Jul;163(1):221-3. doi: 10.1111/j.1365-2133.2010.09782.x. Epub 2010 Mar 24. PubMed PMID: 20346022.

Lee HS, Lee ES. Classic Juvenile Pityriasis Rubra Pilaris Treated with Oral Alitretinoin. Ann Dermatol. 2016 Jun;28(3):388-90. doi: 10.5021/ad.2016.28.3.388. Epub 2016 May 25. PubMed PMID: 27274642; PubMed Central PMCID: PMC4884720.

Yun CH, Kim JS, Ryu HR, Kim JH, Baek JO, Lee JR, Roh JY. Circumscribed juvenile pityriasis rubra pilaris responsive to alitretinoin. Dermatol Ther. 2016 Mar-Apr;29(2):81-3. doi: 10.1111/dth.12320. Epub 2015 Nov 11. PubMed PMID: 26556472.

Amann PM, Susic M, Glüder F, Berger H, Krapf W, Löffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015 Mar;95(3):329-31. doi: 10.2340/00015555-1928. PubMed PMID: 24995552.

Pampín A, Gómez-de la Fuente E, Caro Gutiérrez MD, López-Estebaranz JL. Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin. J Am Acad Dermatol. 2013 Aug;69(2): e105-6. doi: 10.1016/j.jaad.2013.01.036. PubMed PMID: 23866882.

Schmitt L, Inhoff O, Dippel E. Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris. Case Rep Dermatol. 2011 Apr 18;3(1):85-8. doi: 10.1159/000327704. PubMed PMID: 21577368; PubMed Central PMCID: PMC3094680.

Schmitz L, Bierhoff E, Dirschka T. Alitretinoin: an effective treatment option for pagetoid reticulosis. J Dtsch Dermatol Ges. 2013 Dec;11(12):1194-5. doi: 10.1111/ddg.12166. Epub 2013 Jul 23. PubMed PMID: 23879462.

Werchau S, Toberer F, Enk A, Helmbold P. Keratitis-ichthyosis-deafness syndrome: response to alitretinoin and review of literature. Arch Dermatol. 2011 Aug;147(8):993-5. doi: 10.1001/archdermatol.2011.216. Review. PubMed PMID: 21844472.

Foroughipour M, Bahrami Taghanaki HR, Saeidi M, Khazaei M, Sasannezhad P, Shoeibi A. Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. Acupunct Med. 2013 Mar;31(1):27-30. doi: 10.1136/acupmed-2012-010199. Epub 2012 Nov 14. PubMed PMID: 23151355.

Nourbakhsh B, Revirajan N, Waubant E. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemp Clin Trials. 2018 Jan;64:67-76. doi: 10.1016/j.cct.2017.11.005. Epub 2017 Nov 4. PubMed PMID: 29113955.

Yang TT, Wang L, Deng XY, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017 Sep 15;380:256-261. doi: 10.1016/j.jns.2017.07.042. Epub 2017 Jul 28. Review. PubMed PMID: 28870581.

Tur C. Fatigue Management in Multiple Sclerosis. Curr Treat Options Neurol. 2016 Jun;18(6):26. doi: 10.1007/s11940-016-0411-8. Review. PubMed

PMID: 27087457; PubMed Central PMCID: PMC4834309.

Generali JA, Cada DJ. Amantadine: multiple sclerosis-related fatigue. Hosp Pharm. 2014 Sep;49(8):710-2. doi: 10.1310/hpj4908-710. PubMed PMID: 25477595; PubMed Central PMCID: PMC4252198.

Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818. Review. PubMed PMID: 17253480.

Garssen MP, Schmitz PI, Merkies IS, Jacobs BC, van der Meché FG, van Doorn PA. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):61-5. PubMed PMID: 16361594; PubMed Central PMCID: PMC2117395.

Taus C, Giuliani G, Pucci E, D'Amico R, Solari A. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD002818. PubMed PMID: 12804439.

Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology. 1997;35(1):16-23. PubMed PMID: 9018019.

Stein DP, Dambrosia JM, Dalakas MC. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann N Y Acad Sci. 1995 May 25;753:296-302. PubMed PMID: 7611638.

Kemp BA, Gora ML. Amantadine and fatigue of multiple sclerosis. Ann Pharmacother. 1993 Jul-Aug;27(7-8):893-5. Review. PubMed PMID: 8364274.

Hanno PM. Amitriptyline in the treatment of interstitial cystitis. Urol Clin North Am. 1994 Feb;21(1):89-91. Review. PubMed PMID: 8284851.

Giusto LL, Zahner PM, Shoskes DA. An evaluation of the pharmacotherapy for interstitial cystitis. Expert Opin Pharmacother. 2018 Jul;19(10):1097-1108. doi: 10.1080/14656566.2018.1491968. Epub 2018 Jul 4. Review. PubMed PMID: 29972328.

Dancel R, Mounsey A, Handler L. Medications for treatment of interstitial cystitis. Am Fam Physician. 2015 Jan 15;91(2):116-7. PubMed PMID: 25591213.

Generali JA, Cada DJ. Amitriptyline: interstitial cystitis (painful bladder syndrome). Hosp Pharm. 2014 Oct;49(9):809-10. doi: 10.1310/hpj4909-809. PubMed PMID: 25477611; PubMed Central PMCID: PMC4252183.

Sun Y, Fang Z, Ding Q, Zheng J. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate? Neurourol Urodyn. 2014 Mar;33(3):341-4. doi: 10.1002/nau.22407. Epub 2013 Jun 6. PubMed PMID: 23744795.

Offiah I, McMahon SB, O'Reilly BA. Interstitial cystitis/bladder pain syndrome: diagnosis and management. Int Urogynecol J. 2013 Aug;24(8):1243-56. doi: 10.1007/s00192-013-2057-3. Epub 2013 Feb 22. Review. PubMed PMID: 23430074

Yang W, Propert KJ, Landis JR. Estimating the efficacy of an interstitial cystitis/painful bladder syndrome medication in a randomized trial with both non-adherence and loss to follow-up. Stat Med. 2014 Sep 10;33(20):3547-55. doi: 10.1002/sim.5702. Epub 2012 Dec 10. PubMed PMID: 23225539; PubMed Central PMCID: PMC3868645.

Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. Aktuelle Urol. 2010 Jan;41 Suppl 1: S61-5. doi: 10.1055/s-0029-1224651. Epub 2010 Jan 21. PubMed PMID: 20094958.

van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005 Nov;174(5):1837-40. PubMed PMID: 16217303.

van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004 Aug;172(2):533-6. PubMed PMID: 15247722.

Sievert KD, Edenfeld KD, Oberpenning F, Piechota HJ. [Oral therapy of interstitial cystitis]. Urologe A. 2000 Nov;39(6):535-8. Review. German. PubMed PMID: 11138272.

Hanno PM, Wein AJ. Conservative therapy of interstitial cystitis. Semin Urol. 1991 May;9(2):143-7. PubMed PMID: 1712978.

Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urol. 1989 Apr;141(4):846-8. PubMed PMID: 2926877.

Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008242. doi: 10.1002/14651858.CD008242.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD008242. PubMed PMID: 23235657.

Kwiatek R. Treatment of fibromyalgia. Aust Prescr. 2017 Oct;40(5):179-183. doi: 10.18773/austprescr.2017.056. Epub 2017 Oct 3. Review. PubMed PMID: 29109601; PubMed Central PMCID: PMC5662432.

Acet G, Kaya A, Akturk S, Akgol G. A comparison of the effectiveness of amitriptilin and pregabalin treatment in fibromyalgia patients. North Clin Istanb. 2017 Aug 26;4(2):151-159. doi: 10.14744/nci.2017.61687. eCollection 2017. PubMed PMID: 28971173; PubMed Central PMCID: PMC5613263.

Lawson K. A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia. Biomedicines. 2017 May 17;5(2). pii: E24. doi: 10.3390/biomedicines5020024. Review. PubMed PMID: 28536367; PubMed Central PMCID: PMC5489810.

Kia S, Choy E. Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines. 2017 May 8;5(2). pii: E20. doi: 10.3390/biomedicines5020020. Review. PubMed PMID: 28536363; PubMed Central PMCID: PMC5489806.

Sommer C, Alten R, Bär KJ, Bernateck M, Brückle W, Friedel E, Henningsen P, Petzke F, Tölle T, Üçeyler N, Winkelmann A, Häuser W. [Drug therapy of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017 Jun;31(3):274-284. doi: 10.1007/s00482-017-0207-0. Review. German. PubMed PMID: 28493231.

Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Expert Rev Neurother. 2015 Oct;15(10):1123-50. doi: 10.1586/14737175.2015.1091726. Epub 2015 Sep 22. Review. PubMed PMID: 26395929.

Calandre EP, Rico-Villademoros F, Galán J, Molina-Barea R, Vilchez JS, Rodriguez-Lopez CM, Hidalgo-Tallon J, Morillas-Arques P. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl). 2014 Jun;231(12):2525-31. doi: 10.1007/s00213-013-3422-0. Epub 2014 Jan 8. PubMed PMID: 24398824.

Joshi MN, Joshi R, Jain AP. Effect of amitriptyline vs. physiotherapy in management of fibromyalgia syndrome: What predicts a clinical benefit? J Postgrad Med. 2009 Jul-Sep;55(3):185-9. doi: 10.4103/0022-3859.57399. PubMed PMID: 19884743.

Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994 Jan;37(1):32-40. PubMed PMID: 8129762.

Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol. 1991 Mar;18(3):447-51. PubMed PMID: 1856813.

Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996 Jun;8(6):459-76. Review. PMID: 8736630 DOI: 10.2165/00002512-199608060-00008

Urquhart DM, Wluka A, Cicuttini F. Low-Dose Amitriptyline for Chronic Low Back Pain-Reply. JAMA Intern Med. 2019 Mar 1;179(3):450-451. doi: 10.1001/jamainternmed.2018.8145. PubMed PMID: 30830194.

Lin CC, McLachlan AJ, Maher CG. Low-Dose Amitriptyline for Chronic Low Back Pain. JAMA Intern Med. 2019 Mar 1;179(3):450. doi: 10.1001/jamainternmed.2018.8140. PubMed PMID: 30830187.

Kalita J, Misra UK. Low-Dose Amitriptyline for Chronic Low Back Pain. JAMA Intern Med. 2019 Mar 1;179(3):449-450. doi: 10.1001/jamainternmed.2018.8137. PubMed PMID: 30830186.

Urquhart DM, Wluka AE, van Tulder M, Heritier S, Forbes A, Fong C, Wang Y, Sim MR, Gibson SJ, Arnold C, Cicuttini FM. Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 1;178(11):1474-1481. doi: 10.1001/jamainternmed.2018.4222. PubMed PMID: 30285054; PubMed Central PMCID: PMC6248203.

Maarrawi J, Abdel Hay J, Kobaiter-Maarrawi S, Tabet P, Peyron R, Garcia-Larrea L. Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain. Eur J Pain. 2018 Jul;22(6):1180-1187. doi: 10.1002/ejp.1206. Epub 2018 Mar 9. PubMed PMID: 29436064.

Urquhart DM, Wluka AE, Sim MR, van Tulder M, Forbes A, Gibson SJ, Arnold C, Fong C, Anthony SN, Cicuttini FM. Is low-dose amitriptyline effective in the management of chronic low back pain? Study protocol for a randomised controlled trial. Trials. 2016 Oct 22;17(1):514. PubMed PMID: 27770809; PubMed Central PMCID: PMC5075416.

Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A, Kozek-Langenecker SA. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr. 2005 Nov;117(21-22):761-8. PubMed PMID: 16416358.

Rizzatti-Barbosa CM, Nogueira MT, de Andrade ED, Ambrosano GM, de Barbosa JR. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio. 2003 Jul;21(3):221-5. PubMed PMID: 12889679.

Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil. 2000 Oct;27(10):834-41. PubMed PMID: 11065017.

Gumus II, Sarifakioglu E, Uslu H, Turhan NO. Vulvodynia: case report and review of literature. Gynecol Obstet Invest. 2008;65(3):155-61. Epub 2007 Nov 13. Review. PubMed PMID: 17998784.

Murphy D, Redman C, Thomas E. Essential vulvodynia (vulval pain). Clin Evid. 2002 Dec;(8):1875-7. Review. PubMed PMID: 12603974.

Murphy D, Redman C, Thomas E. Essential vulvodynia (vulval pain). Clin Evid. 2002 Jun;(7):1663-5. Review. Update in: Clin Evid. 2002 Dec;(8):1875-7. PubMed PMID: 12230779.

Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012 May;79(3):330-1. doi: 10.1016/j.jbspin.2011.12.017. Epub 2012 Feb 15. PubMed PMID: 22341584.

Peciuliene S, Burnyte B, Gudaitiene R, Rusoniene S, Drazdiene N, Liubsys A, Utkus A. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra. Pediatr Rheumatol Online J. 2016 Mar 25;14(1):19. doi: 10.1186/s12969-016-0081-9. Review. PubMed PMID: 27012807; PubMed Central PMCID: PMC4807578.

Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology. 2011;222(2):123-7. doi: 10.1159/000326112. Epub 2011 Apr 5. PubMed PMID: 21464561.

Pecher AC, Igney-Oertel A, Kanz L, Henes J. Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine. Scand J Rheumatol. 2017 Sep;46(5):407-409. doi: 10.1080/03009742.2016.1245780. Epub 2017 Jan 18. PubMed PMID: 28097903.

Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015 Aug;45(1):81-5. doi: 10.1016/j.semarthrit.2015.02.006. Epub 2015 Feb 20. PubMed PMID: 25795473.

Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, Vassilopoulos D. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014 Dec;73(12):2215-7. doi: 10.1136/annrheumdis-2014-205990. Epub 2014 Aug 27. PubMed PMID: 25165036

Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a

patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014 Jan;170(1):202-4. doi: 10.1111/bjd.12548. PubMed PMID: 23909475.

Szturz P, Sedivá A, Zurek M, Adam Z, Stork J, Cermáková Z, Steyerová P, Vokáčová A, Hrbek J, Sýkora M, Spička I, Mechl Z, Mayer J. [Anakinra treatment in Schnitzler syndrome - results of the first retrospective multicenter study in six patients from the Czech Republic]. Klin Onkol. 2014;27(2):111-26. Czech. PubMed PMID: 24739048.

Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis. 2012 Jun;71(6):1098-100. doi: 10.1136/annrheumdis-2011-200743. Epub 2012 Jan 4. PubMed PMID: 22219141.

Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005 Dec;16(12):1487-94. Epub 2005 Apr 23. PubMed PMID: 15856361.

Ring JD, Lwin AA, Köhler TS. Current medical management of endocrine-related male infertility. Asian J Androl. 2016 May-Jun;18(3):357-63. doi:10.4103/1008-682X.179252. Review. PubMed PMID: 27098657; PubMed Central PMCID: PMC4854080

Bettencourt M. Oral Lichen Planus Treated With Apremilast. J Drugs Dermatol. 2016 Aug 1;15(8):1026-8. PubMed PMID: 27538007.

Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2000 Apr;73(4):718-23. PubMed PMID: 10731531

Bassetti CL, Bornatico F, Fuhr P, Schwander J, Kallweit U, Mathis J; Swiss RLS study group. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly. 2011 Nov 21;141:w13274. doi: 10.4414/smw.2011.13274. eCollection 2011. PubMed PMID: 22101745.

Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014 May;120(5):1262-74. doi: 10.1097/ALN.0000000000000170.Review. PubMed PMID: 24509068; PubMed Central PMCID: PMC3999180.

My doctor prescribed Sinemet for my restless legs and it was a catastrophe. Why did you recommend it in a recent article? Johns Hopkins Med Lett Health After 50. 1998 Feb;10(12):8. PubMed PMID: 9916583.

Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15(8):851-6. doi: 10.1586/14737175.2015.1066675. Epub 2015 Jul 7. Review. PubMed PMID: 26154918.

Johannsson V, Nilsson LR, Widelius T, Jäverfalk T, Hellman P, Akesson JA, Olerud B, Gustafsson CL, Raak A, Sandahl G, et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache. 1987 Jul;27(7):372-4. PubMed PMID: 3308768.

Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989 Nov;121(5):639-46. PubMed PMID: 2688737.

Jones RR. Azathioprine therapy in the management of persistent erythema multiforme. Br J Dermatol. 1981 Oct;105(4):465-7. PubMed PMID: 7295560.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. PubMed PMID: 22607134; PubMed Central PMCID: PMC3422642.

Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011 Apr;147(4):474-88. doi: 10.1001/archdermatol.2011.79. Review. PubMed PMID: 21482898.

Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol. 2001 Oct-Nov;81(5):378-9. PubMed PMID: 11800155.

Thandar Y, Maharajh R, Haffejee F, Mosam A. Treatment of Cutaneous Lichen Planus (Part 2): A Review of Systemic Therapies. J Dermatolog Treat. 2018 Nov 17:1-40. doi: 10.1080/09546634.2018.1544411. [Epub ahead of print] PubMed PMID:30451042.

Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011 Apr;147(4):474-88. doi: 10.1001/archdermatol.2011.79. Review. PubMed PMID: 21482898.

Chainani-Wu N, Silverman S Jr, Lozada-Nur F, Mayer P, Watson JJ. Oral lichen planus: patient profile, disease progression and treatment responses. J Am Dent Assoc. 2001 Jul;132(7):901-9. PubMed PMID: 11480643.

Verma KK, Sirka CS, Khaitan BK. Generalized severe lichen planus treated with azathioprine. Acta Derm Venereol. 1999 Nov;79(6):493. PubMed PMID: 10598780.

Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol. 1996 Jan;21(1):56-7. PubMed PMID: 8689773.

Klein LR, Callen JP. Azathioprine: effective steroid-sparing therapy for generalized lichen planus. South Med J. 1992 Feb;85(2):198-201. PubMed PMID: 1738890.

Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991 Dec;72(6):665-70. PubMed PMID: 1812447.

Dube M, Sodani A, Chouksey D. Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India. Acta Neurol Taiwan. 2017 Sep 15;26(3):106-119. PubMed PMID: 29468619.

Neurology. 1998 Jun;50(6):1778-83.A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

Palace J1, Newsom-Davis J, Lecky B. PMID: 9633727

Neuromuscul Disord. 1991;1(6):423-31. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Kuks JB1, Djojoatmodjo S, Oosterhuis HJ. PMID: 1822354.

Pharmacogenet Genomics. 2017 Feb;27(2):51-56. doi: 10.1097/FPC.0000000000000257. A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis. Colleoni L1, Galbardi B, Barzago C, Bonanno S, Franzi S, Frangiamore R, Camera G, Foti M, Biancolini D, Canioni E, Maggi L, Antozzi C, Mantegazza R, Bernasconi P, Kapetis D. PMID: 27922550 DOI:10.1097/FPC.0000000000000257.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):486-493. doi: 10.1111/bcpt.13034. Epub 2018 Jun 13. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013. Pedersen EG1, Hallas J2, Pottegård A2, Hald SM1, Jensen PEH3, Gaist D1. PMID: 29732733 DOI: 10.1111/bcpt.13034.

Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011 Aug 16;77(7):659-66. doi: 10.1212/WNL.0b013e31822a2780. Epub 2011 Aug 3. PubMed PMID: 21813788.

Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol. 1989 Oct;125(10):1377-9. PubMed PMID: 2802645.

Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972 Jul;87(1):42-5. PubMed PMID: 5043197.

Schram ME1, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011 Apr;147(4):474-88. doi: 10.1001/archdermatol.2011.79. PMID: 21482898 DOI: 10.1001/archdermatol.2011.79

J Dermatol Surg Oncol. 1984 Jun;10(6):462-4. Azathioprine for use in dermatology. Gendler E. PMID: 6725741.

Ahmed AR, Moy R. Azathioprine. Int J Dermatol. 1981 Sep;20(7):461-7. PMID: 7026466

Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972 Jul;87(1):42-5. PMID: 5043197.

Bünger P, Delventhal G. [Azathioprine therapy in a severe case of "Lyell's syndrome"]. Z Haut Geschlechtskr. 1968 Oct 15;43(20):853-60. German. PubMed PMID: 5702929.

Banchs HL, Carro Jiménez EJ, González V, González Cancel IF, Quintana C, Calderón R, Altieri PI, Rivera C. Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico. Bol Asoc Med P R. 2007 Jul-Sep;99(3):191-6. PubMed PMID: 19610574

Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, Pinto A. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20.

Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas. Technol Eval Cent Assess Program Exec Summ. 2009 Oct;24(4):1-3. PubMed PMID: 20183930.

Halderman AA, Ryan MW, Marple BF, Sindwani R, Reh DD, Poetker DM. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review. Am J Rhinol Allergy. 2018 Jul;32(4):258-268. doi: 10.1177/1945892418768588. Epub 2018 May 10. Review. PubMed PMID: 29745243.

Carifi M, Napolitano D, Morandi M, Dall'Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015 May 5;11:731-8. doi: 10.2147/TCRM.S81825. eCollection 2015. Review. PubMed PMID: 25999724; PubMed Central PMCID: PMC4427257.

Liu J, Xu JH, Xu W, Liang GL, Lou JX, Wang Y, Wen JQ, Cao YB. Bevacizumab as adjuvant therapy in the management of pterygium: a systematic review and Meta-analysis. Int J Ophthalmol. 2017 Jul 18;10(7):1126-1133. doi: 10.18240/ijo.2017.07.17. eCollection 2017. PubMed PMID: 28730117; PubMed Central PMCID: PMC5514276.

Şahin A, Gürsel-Özkurt Z, Şahin M, Türkcü FM, Yıldırım A, Yüksel H. Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity. Ir J Med Sci. 2018 May;187(2):417-421. doi: 10.1007/s11845-017-1684-y. Epub 2017 Oct 7. PubMed PMID: 28988372.

Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost. Plast Surg Nurs. 2015 Apr-Jun;35(2):82-91. doi: 10.1097/PSN.0000000000000097. PubMed PMID: 26020474.

Riahi RR, Cohen PR. Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review. Cureus. 2018 May 21;10(5):e2666. doi: 10.7759/cureus.2666. PubMed PMID: 30042917; PubMed Central PMCID: PMC6054329.

Peabody T1, Reitz S, Smith J, Teti B. Clinical management of trichotillomania with bimatoprost. Optom Vis Sci. 2013 Jun;90(6):e167-71. doi: 10.1097/OPX.0b013e318294c158. PMID: 23645373.

Morris CL1, Stinnett S, Woodward J. The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: an analysis of efficacy and safety. Int J Trichology. 2011 Jul;3(2):84-91. doi: 10.4103/0974-7753.90809. PMID: 22223967 PMCID: PMC3250027 DOI: 10.4103/0974-7753.90809.

Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010 Dec;88(8):896-900. doi: 10.1111/j.1755-3768.2009.01582.x. PubMed PMID: 19725815.

Campa C, Salsini G, Perri P. Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial. Curr Eye Res. 2018 Mar;43(3):362-367. doi: 10.1080/02713683.2017.1396615. Epub 2017 Nov 9. PubMed PMID: 29120255.

Miyanaga M1, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol. 2009 May;87(3):300-5. Epub 2009 Jan 31. PMID: 19183412 DOI: 10.1111/j.1755-3768.2008.01433.x

Giannaccare G, Finzi A, Sebastiani S, Greco F, Versura P, Campos EC. The Comparative Efficacy and Tolerability of Diclofenac 0.1% and Bromfenac 0.09% Ophthalmic Solutions after Cataract Surgery. Curr Eye Res. 2018 Dec;43(12):1445-1453. doi: 10.1080/02713683.2018.1501489. Epub 2018 Jul 27. PubMed PMID: 30009640.

Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017 May 11;27(3):326-330. doi: 10.5301/ejo.5000888. Epub 2016 Nov 16. PubMed PMID:28009414.

Cardascia N, Palmisano C, Centoducati T, Alessio G. Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery. Int Ophthalmol. 2017 Oct;37(5):1127-1131. doi:10.1007/s10792-016-0374-5. Epub 2016 Oct 20. PubMed PMID: 27766540.

Lim BX, Lim CH, Lim DK, Evans JR, Bunce C, Wormald R. Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery. Cochrane Database Syst Rev. 2016 Nov 1;11:CD006683. Review. PubMed PMID: 27801522.

Chinchurreta Capote AM, Lorenzo Soto M, Rivas Ruiz F, Caso Peláez E, García Vazquez A; Group OftaCosta, Ramos Suárez A. Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification. Int J Ophthalmol. 2018 Jul 18;11(7):1210-1216. doi: 10.18240/ijo.2018.07.22. eCollection 2018. PubMed PMID: 30046541; PubMed Central PMCID: PMC6048336.

Palacio C, Fernández De Ortega L, Bustos FR, Chávez E, Oregon-Miranda AA, Mercado-Sesma AR. Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population. Clin Ophthalmol. 2016 Jan 27;10:233-7. doi: 10.2147/OPTH.S93530. eCollection 2016. PubMed PMID: 26869758; PubMed Central PMCID: PMC4734805.

Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol. 1988 Sep;24(3):455-8. PubMed PMID: 3067654.

Wesseling GJ, Quaedvlieg M, Wouters EF. Inhaled budesonide in chronic bronchitis. Effects on respiratory impedance. Eur Respir J. 1991 Oct;4(9):1101-5. PubMed PMID: 1756844.

Schmelz R, Bornhäuser M, Schetelig J, Kiani A, Platzbecker U, Schwanebeck U, Grählert X, Uharek L, Aust D, Baretton G, Schwerdtfeger R, Hampe J, Greinwald R, Mueller R, Ehninger G, Miehlke S. Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST). BMC Gastroenterol. 2014 Nov 26; 14: 197. doi: 10.1186/s12876-014-0197-7. PubMed PMID: 25425214; PubMed Central PMCID: PMC4258813.

Kurada S, Yadav A, Leffler DA. Current and novel therapeutic strategies in celiac disease. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1211-23. doi: 10.1080/17512433.2016.1200463. Epub 2016 Jun 23. Review. PubMed PMID: 27322016.

Barlan IB, Erkan E, Bakir M, Berrak S, Başaran MM. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol. 1997 Jun;78(6):598-601. PubMed PMID: 9207726.

Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999 Jun;19(3):268-71. PubMed PMID: 10350034.

Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012 Nov;10(11):1239-45. doi: 10.1016/j.cgh.2012.06.036. Epub 2012 Jul 17. PubMed PMID: 22813445.

Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs. 1995 Feb;49(2):255-79. Review. PubMed PMID: 7729332.

Porter MC, Appiah-Kubf LS, Chaudhuri KR. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting

dopamine agonist. Int J Clin Pract. 2002 Jul-Aug;56(6):468-74. Review. PubMed PMID: 12166546.

Tran TA, Pariente D, Guitton C, Delwail A, Barat-Houari M, Meinzer U. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology (Oxford). 2014 Dec;53(12):2312-4. doi:10.1093/rheumatology/keu344. Epub 2014 Sep 17. PubMed PMID: 25234662.

Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014 Jul;81(4):376-7. doi: 10.1016/j.jbspin.2013.12.011. Epub 2014 Jan 23. PubMed PMID: 24462130.

Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V, Cimaz R. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 2013 Feb;65(2):513-8. doi: 10.1002/art.37776. PubMed PMID: 23124805; PubMed Central PMCID: PMC3684148.

Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum. 2013 Feb;42(4):413-6. doi: 10.1016/j.semarthrit.2012.06.003. Epub 2012 Aug 15. PubMed PMID: 22901459.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):65-9. PubMed PMID: 12503978.

Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;(10):CD004233. doi: 10.1002/14651858.CD004233.pub4. Review. PubMed PMID: 24150982.

Yang S, Wang X, Jiang H, Wang Y, Li Z, Lu H. Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing. Cancer Biol Ther. 2017 Oct 3;18(10):757-760. doi: 10.1080/15384047.2017.1373215. Epub 2017 Sep 7. PubMed PMID: 28881160; PubMed Central PMCID: PMC5678687.

Augustine JM, Lee JK, Armstrong EP. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680. Review. PubMed PMID: 25209304.

Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther. 2014 May;14(5):583-600. doi: 10.1517/14712598.2014.885945. Epub 2014 Feb 6. Review. PubMed PMID: 24502344.

Yarali N, Fişgin T, Kara A, Duru F. Successful management of severe chronic autoimmune hemolytic anemia with low dose cyclosporine and prednisone in an infant. Turk J Pediatr. 2003 Oct-Dec;45(4):335-7. PubMed PMID: 14768800.

Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1987 Apr;16(4):890. PubMed PMID: 3571559.

Tao JL, Liu LL, Wen YB, Gao RT, Li H, Li MX, Li XM, Li XW. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years. Chin Med J (Engl). 2011 Nov;124(21):3490-4. PubMed PMID: 22340164.

Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, Liu Z, Li L. Cyclosporin A treatment for idiopathic membranous nephropathy. Chin Med J (Engl). 2001 Dec;114(12):1305-8. PubMed PMID: 11793859.

Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol. 1997 Sep;244(9):542-7. PubMed PMID: 9352450.

Özdemir Ö, Atalay CR, Asgarova V, Ilgin BU. A resistant case of pemphigus gestationis successfully treated with cyclosporine. Interv Med Appl Sci. 2016 Mar;8(1):20-22. doi: 10.1556/1646.8.2016.1.3. PubMed PMID: 28250977; PubMed Central PMCID: PMC5322493.

Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M, Turchetta R, Pagliuca G, DE Vincentiis M. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital. 2014 Dec;34(6):375-81. Review. PubMed PMID: 25762828; PubMed Central PMCID: PMC4346993.

Støa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int J Obes Relat Metab Disord. 1998 Nov;22(11):1041-5. PubMed PMID: 9822940.

Fozza C. The role of Clofarabine in the treatment of adults with acute myeloid leukemia. Crit Rev Oncol Hematol. 2015 Mar;93(3):237-45. doi: 10.1016/j.critrevonc.2014.10.009. Epub 2014 Oct 22. Review. PubMed PMID: 25457773.

Roth LW, Ryan AR, Meacham RB. Clomiphene citrate in the management of male infertility. Semin Reprod Med. 2013 Jul;31(4):245-50. doi: 10.1055/s-0033-1345271. Epub 2013 Jun 17. Review. PubMed PMID: 23775379.

Mahmood T, Devlin M, Silverstone T. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment. Aust N Z J Psychiatry. 1997 Jun;31(3):424-6. PubMed PMID: 9226089.

http://www.therapeutique-dermatologique.org/spip.php?article1094

Goddard CJ, Whorwell PJ. Amiodarone overdose and its management. Br J Clin Pract. 1989 May;43(5):184-6. PubMed PMID: 2590638.

Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002 Jul 15;100(2):704-6. PubMed PMID: 12091370.

Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis Rheumatol. 2018 May;70(5):785-793. doi: 10.1002/art.40418. Epub 2018 Mar 25. PubMed PMID: 29342499; PubMed Central PMCID: PMC5947636.

Nagappa M, Netravathi M, Taly AB, Sinha S, Bindu PS, Mahadevan A. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci. 2014 Nov;21(11):1909-14. doi: 10.1016/j.jocn.2014.03.019. Epub 2014 Jul 17. PubMed PMID: 25043165.

Vanstreels L, Alkhateeb A, Megahed M. [Pemphigus vulgaris. Therapy with cyclophosphamide]. Hautarzt. 2013 May;64(5):330-2. doi: 10.1007/s00105-013-2553-x. German. PubMed PMID: 23571646.

Pawlowski GJ. Cyproheptadine: weight-gain and appetite stimulation in essential anorexic adults. Curr Ther Res Clin Exp. 1975 Nov;18(5):673-8. PubMed PMID: 812645.

De Leo V, Morgante G. Different effectiveness of cyproterone acetate doses in treatment of acne. Clin Endocrinol (Oxf). 2003 Feb;58(2):246. PubMed PMID:12580942.

Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102(1):1-32. Review. PubMed PMID: 8005205.

Moran C. Important effects of cyproterone acetate on endometriosis? Fertil Steril. 2002 Oct;78(4):886; author reply 886-7. PubMed PMID: 12372480.

Maloisel F, Andrès E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004 May 1;116(9):590-4. PubMed PMID: 15093754.

Ahn YS, Harrington WJ, Mylvaganam R, Ayub J, Pall LM. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med. 1985 Mar;102(3):298-301. PubMed PMID: 3970469.

Goutelle S, Roux S, Gagnieu MC, Valour F, Lustig S, Ader F, Laurent F, Chidiac C, Ferry T. Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3148-51. doi: 10.1128/AAC.02597-15. Print 2016 May.

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013 Jun 24;(6):CD010611. doi: 10.1002/14651858.CD010611. Review. PubMed PMID: 23797677.

Jones W, Breward S. Use of domperidone to enhance lactation: what is the evidence? Community Pract. 2011 Jun;84(6):35-7. PubMed PMID: 21739859.

Rossignol DA, Frye RE. The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review. Front Pediatr. 2014 Aug 22; 2: 87. doi: 10.3389/fped.2014.00087. eCollection 2014. Review. PubMed PMID: 25202686; PubMed Central PMCID: PMC4141213.

Rizkallah J, Kuriachan V, Brent Mitchell L. The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature. BMC Res Notes. 2016 Jul 27; 9: 370. doi: 10.1186/s13104-016-2116-1. PubMed PMID: 27461025; PubMed Central PMCID: PMC4962476.

Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD007115. DOI: 10.1002/14651858.CD007115.pub2. PMID: 24385423. DOI: 10.1002/14651858.CD007115.pub3.

Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2014 Feb;83(2):400-5. doi: 10.1016/j.urology.2013.09.024. Epub 2013 Nov 12. PubMed PMID: 24231216.

Sweeney DD, Chancellor MB. Treatment of stress urinary incontinence with duloxetine hydrochloride. Rev Urol. 2005 Spring;7(2):81-6. PubMed PMID: 16985814.

van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol. 2007 Feb;177(2):552-5. PubMed PMID: 17222632.

Arnold LM, Blom TJ, Welge JA, Mariutto E, Heller A. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. Psychosomatics. 2015 May-Jun;56(3):242-53. doi: 10.1016/j.psym.2014.12.003. Epub 2014 Dec 16. PubMed PMID: 25660434.

Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. [Duloxetine in the treatment of chronic migraine]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):49-54. Russian. PubMed PMID: 20436437.

Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1): S28-S36. doi: 10.1016/j.jaad.2017.12.022. Review. PubMed PMID: 29471919.

Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014 Nov-Dec;80(6):521-5. doi: 10.4103/0378-6323.144162. PubMed PMID: 25382509.

Johnson CK, Leca N. Eculizumab use in kidney transplantation. Curr Opin Organ Transplant. 2015 Dec; 20(6): 643-51. doi: 10.1097/MOT.0000000000000249. Review. PubMed PMID: 26536427.

Qureshi ZA, Syed A, Doi Y. Safety and efficacy of long-term outpatient ertapenem therapy. Antimicrob Agents Chemother. 2014 Jun;58(6):3437-40. doi: 10.1128/AAC.02721-14. Epub 2014 Apr 7.

Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010 Mar;55(3):675-83. doi: 10.1007/s10620-009-1038-3. PubMed PMID: 19924535.

Garcia-Escrivà A, López-Herandez N, Lezcano M, Berenguer L. Experience with eslicarbazepine acetate as treatment for painful diabetic neuropathy. Neurologia. 2016 Nov - Dec;31(9):639-640. doi: 10.1016/j.nrl.2014.10.013. Epub 2015 Feb 11. English, Spanish. PubMed PMID: 25681850.

Famularo G, Di Dona B, Canzona F, Girardelli CR, Cruciani G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007 Jun;41(6):1083-4. Epub 2007 Apr 24. PubMed PMID: 17456541.

Watson IT, Haugh I, Gardner AR, Menter MA. Histiocytoid Sweet syndrome successfully treated with etanercept. Proc (Bayl Univ Med Cent). 2018 May 9;31(3):347-349. doi: 10.1080/08998280.2018.1460132. eCollection

2018 Jul. PubMed PMID: 29904308; PubMed Central PMCID: PMC5997035.

Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol. 2005;6(2):93-103. Review. PubMed PMID: 15799681.

Bedi MK. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept. Skinmed. 2007 Sep-Oct;6(5):245-7. PubMed PMID: 17786105.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. PubMed PMID: 28781108; PubMed Central PMCID: PMC5831666.

Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015 Jul;47(8):560-4. doi: 10.1055/s-0034-1387793. Epub 2014 Sep 17. PubMed PMID: 25230325.

Karalapillai D, Popham P. Recombinant factor VIIa in massive postpartum haemorrhage. Int J Obstet Anesth. 2007 Jan;16(1):29-34. Epub 2006 Nov 27. Review. PubMed PMID: 17125989.

Wu YY. [Efficacy and safety of famotidine for the treatment of stress ulcers in neonates]. Zhongguo Dang Dai Er Ke Za Zhi. 2008 Oct;10(5):593-5. Chinese. PubMed PMID: 18947477.

Kraut EH, Chun HG. Fludarabine phosphate in refractory hairy cell leukemia. Am J Hematol. 1991 May;37(1):59-60. PubMed PMID: 1708945.

Hochster H, Cassileth P. Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol. 1990 Oct;17(5 Suppl 8):63-5. PubMed PMID: 1699284.

Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990 May 15;75(10):1928-31. PubMed PMID: 1692487.

Bordonaro R, Ferraù F, Giuffrida D, Calì S, Priolo D, Colina P, Ursino M, Failla G. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report. Tumori. 1999 Jul-Aug;85(4):288-9. Review. PubMed PMID: 10587034.

Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol. 2004 Feb;150(2):327-36. PubMed PMID: 14996105.

Boztosun A, Açmaz G, Ozturk A, Müderris II. Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome. Ginekol Pol. 2013 Apr;84(4):258-62. PubMed PMID: 23700857.

B, Klamroth R, Hankowitz J, Banik N, Eberle S, Kropff S, Müller MM, Lindhoff-Last E. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study. Thromb Res. 2014 Jul;134(1):29-35.doi: 10.1016/j.thromres.2014.03.029.

Adair CD, Buckalew VM, Kipikasa J, Torres C, Stallings SP, Briery CM. Repeated dosing of digoxin-fragmented antibody in preterm eclampsia. J Perinatol. 2009 Feb;29(2):163-5. doi: 10.1038/jp.2008.181. PubMed PMID: 19177044.

Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan;174(1):70-7. doi: 10.1001/jamainternmed.2013.11950. PubMed PMID: 24190578; PubMed Central PMCID: PMC3920987.

Kelsberg G, Maragh L, Safranek S. Clinical Inquiry: Which nonhormonal treatments are effective for hot flashes? J Fam Pract. 2016 May;65(5): E1-3. PubMed PMID: 27275942

Hansen HC. Interstitial cystitis and the potential role of gabapentin. South Med J. 2000 Feb;93(2):238-42. Review. PubMed PMID: 10701800.

Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and

fibromyalgia in adults. Cochrane Database Syst Rev. 2014 Apr 27;(4):CD007938. doi: 10.1002/14651858.CD007938.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. PubMed PMID: 24771480.

Fogleman CD. Gabapentin for the prophylaxis of episodic migraine in adults. Am Fam Physician. 2014 May 1;89(9):714-5. Review. PubMed PMID: 24784332.

Kumar V, Ambekar N, Singh A, Venkatasubramanian G. Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin. Asian J Psychiatr. 2014 Jun; 9: 89-90. doi: 10.1016/j.ajp.2014.01.010. Epub 2014 Feb 6. PubMed PMID: 24813045.

Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul;15(4):678-82. PubMed PMID: 10928578.

Chang CY, Challa CK, Shah J, Eloy JD. Gabapentin in acute postoperative pain management. Biomed Res Int. 2014; 2014: 631756. doi: 10.1155/2014/631756. Epub 2014 Apr 14. Review. PubMed PMID: 24829909; PubMed Central PMCID: PMC4009126.

Peterson CD, Leeder JS, Sterner S. Glucagon therapy for beta-blocker overdose. Drug Intell Clin Pharm. 1984 May;18(5):394-8. PubMed PMID: 6144498.

Shenoy S, Lankala S, Adigopula S. Management of calcium channel blocker overdoses. J Hosp Med. 2014 Oct;9(10):663-8. doi: 10.1002/jhm.2241. Epub 2014 Jul 28. Review. PubMed PMID: 25066023.

Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group. Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13. PubMed PMID: 29027693.

Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, Gerardo DS, Iannone F, Frediani B, Galeazzi M, Lapadula G, Rigante D, Cantarini L. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clin Rheumatol. 2017 Sep;36(9):2063-2069. doi: 10.1007/s10067-017-3627-4. Epub 2017 Apr 11. Erratum in: Clin Rheumatol. 2018 Sep 22. PubMed PMID: 28401434.

www.sfar.org/wp-content/uploads/2016/09/Intoxication-aux-anesthesiques-locaux.pdf

Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997 May;49(5A Suppl):108-10. PubMed PMID: 9146011.

Bas M. The Angiotensin-Converting-Enzyme-Induced Angioedema. Immunol Allergy Clin North Am. 2017 Feb;37(1):183-200. doi: 10.1016/j.iac.2016.08.011. Review. PubMed PMID: 27886906.

Zanichelli A, Maurer M, Aberer W, Caballero T, Longhurst HJ, Bouillet L, Fabien V, Andresen I; IOS Study Group. Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. Allergy. 2017 Jun;72(6):994-998. doi: 10.1111/all.13103. Epub 2017 Mar 13. Erratum in: Allergy. 2018 Sep;73(9):1929. PubMed PMID: 27926986; PubMed Central PMCID: PMC5434903.

Hoeper MM, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange TJ, Grünig E, Seeger W, Ewert R, Borst MM, Welte T, Rosenkranz S, Ghofrani HA. [Imatinib for pulmonary arterial hypertension]. Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4: S151-4. doi: 10.1055/s-0034-1387457. Epub 2014 Dec 9. Review. German. PubMed PMID: 25489685.

Wcislo G, Szarlej-Wcislo K, Szczylik C. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol. 2007 Aug;133(8):533-8. Epub 2007 Apr 24. Review. PubMed PMID: 17453242.

Gilja I, Radej M, Kovacić M, Parazajder J. Conservative treatment of female stress incontinence with imipramine. J Urol. 1984 Nov;132(5):909-11. PubMed PMID: 6541710.

Ganjian S, Ourian AJ, Shamtoub G, Wu JJ, Murase JE. Off-label indications for imiquimod. Dermatol Online J. 2009 May 15;15(5):4. Review. PubMed PMID: 19624982.

Gupta S, Khurana AK, Ahluwalia BK, Gupta NC. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol (Copenh). 1991 Feb;69(1):95-8. PubMed PMID: 2028777.

Prakash S, Shah ND, Chavda BV. Cluster headache responsive to indomethacin: Case reports and a critical review of the literature. Cephalalgia. 2010 Aug;30(8):975-82. doi: 10.1177/0333102409357642. Epub 2010 Mar 12. Review. PubMed PMID: 20656709.

Lankarani KB. Infliximab for treatment of pyoderma gangrenosum. Neth J Med. 2015 Aug;73(7):357. PubMed PMID: 26314725.

Sharma PK, Markov GT, Bajwa A, Foster CS. LONG-TERM EFFICACY OF SYSTEMIC INFLIXIMAB IN RECALCITRANT RETINAL VASCULITIS. Retina. 2015 Dec;35(12):2641-6. doi: 10.1097/IAE.0000000000000624. PubMed PMID: 26200508.

van Rappard DC, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review. J Dermatolog Treat. 2013 Oct;24(5):392-404. doi: 10.3109/09546634.2012.674193. Epub 2012 Apr 12. Review. PubMed PMID: 22397574.

Braun SA, Homey B, Gerber PA. [Successful treatment of Bowen disease with ingenol mebutate]. Hautarzt. 2014 Oct;65(10):848-50. doi: 10.1007/s00105-014-3509-5. German. PubMed PMID: 25217087.

Beta-blocker poisoning. Lancet. 1980 Apr 12;1(8172):803-4. PubMed PMID: 6102685.

Parodi A, Drago F, Paolino S, Cozzani E, Gallo R. Treatment of rosacea. Ann Dermatol Venereol. 2011 Nov;138 Suppl 3: S211-4. doi: 10.1016/S0151-9638(11)70092-8. PubMed PMID: 22183101.

Akyol M, Ozçelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol. 2005;6(3):175-84. Review. PMID:15943494

Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986 Dec 11;315(24):1501-5. PubMed PMID: 3537787.

Dicken CH, Bauer EA, Hazen PG, Krueger GG, Marks JG Jr, McGuire JS, Schachner LA. Isotretinoin treatment of Darier's disease. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):721-6. PubMed PMID: 7040515.

Del Rosso JQ, Horowitz DC. Treatment of Darier's disease with isotretinoin: report of a case. J Am Osteopath Assoc. 1986 Oct;86(10):634-8. PubMed PMID: 3465715.

Burge SM, Buxton PK. Topical isotretinoin in Darier's disease. Br J Dermatol. 1995 Dec;133(6):924-8. PubMed PMID: 8547046.

Huen AO, Kim EJ. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin. 2015 Oct; 33(4): 715-29. doi: 10.1016/j.det.2015.05.007. Epub 2015 Aug 4. Review. Erratum in: Dermatol Clin. 2018 Jul;36(3): xiii. PubMed PMID: 26433844.

Wei Li, Ying Liu, Quan Luo, Xue-Mei Li, Xi-Bao Zhang. OFF-LABEL USES OF RETINOIDS IN DERMATOLOGY. Our Dermatol Online. 2012; 3(Suppl. 1): 259-278. DOI: 10.7241/ourd.20124.62

Annamaria M, Lupo PP, Foresti S, De Ambroggi G, de Ruvo E, Sciarra L, Cappato R, Calo L. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol. 2016 Jun;46(1):47-53. doi: 10.1007/s10840-015-0066-5. Epub 2015 Oct 14. Review. PubMed PMID: 26467151.

Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Jun;18(3):195-204. doi: 10.1007/s40256-017-0252-1. Review. PubMed PMID: 29330767.

Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014 Feb;77(2):357-67. doi: 10.1111/bcp.12094. Review. PubMed PMID: 23432384; PubMed Central PMCID: PMC4014022.

Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993 Jul-Aug;38 Suppl:141-8. PubMed PMID: 8236005.

Alcántara-Montero A, Sánchez-Carnerero CI. Lacosamide and neuropathic pain, a review. Rev Neurol. 2016 Mar 1;62(5):223-9. Review. Spanish. PMID:26916326.

Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD009318. doi: 10.1002/14651858.CD009318.pub2. Review. PMID: 22336864.

Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1730-2. PubMed PMID: 16291905; PubMed Central PMCID: PMC1739463.

Shaikh S, Yaacob HB, Abd Rahman RB. Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. J Chin Med Assoc. 2011 Jun;74(6):243-9. doi: 10.1016/j.jcma.2011.04.002. Epub 2011 May 10. PubMed PMID: 21621166.

Liu C, Feng G, Huang W, Wang Q, Yang S, Tan J, Fu J, Liu D. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol. 2017 Nov;33(11):872-876. doi: 10.1080/09513590.2017.1332174. Epub 2017 May 30. PubMed PMID: 28557652.

Martínez-Granero MA, García-Pérez A, Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatr Dis Treat. 2010 Jun 24;6: 309-16. PubMed PMID: 20628631; PubMed Central PMCID: PMC2898169.

Rigamonti A, Lauria G, Grimod G, Bianchi G, Salmaggi A. Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine. J Clin Neurosci. 2014 Apr;21(4):690-1. doi: 10.1016/j.jocn.2013.04.033. Epub 2013 Oct 8. Review. PubMed PMID: 24119342.

Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, Jang SH, Yoo KH, Jung KH, Kim KU, Choi SB, Ryu YJ, Chan Kim K, Um S, Kwon YS, Kim YH, Choi WI, Jeon K, Hwang YI, Kim SJ, Lee YS, Heo EY, Lee J, Ki YW, Shim TS, Yim JJ. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013 Oct 1;188(7):858-64. doi: 10.1164/rccm.201303-0604OC. PubMed PMID: 23927582.

Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. Minerva Med. 2018 Oct;109(5):344-351. doi: 10.23736/S0026-4806.18.05690-2. Epub 2018 May 31. PubMed PMID: 29856191.

Muñoz P, Rodríguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E, Game Study Group. Linezolid therapy for infective endocarditis. Clin Microbiol Infect. 2007 Feb;13(2):211-215. doi: 10.1111/j.1469-0691.2006.01585.x. PubMed PMID: 17328738.

Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015 Jul;47(8):560-4. doi: 10.1055/s-0034-1387793. Epub 2014 Sep 17. PubMed PMID: 25230325.

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001 Jan 6;322(7277):19-22. PubMed PMID: 11141144; PubMed Central PMCID: PMC26600.

Manzoni GC, Terzano MG. Lithium carbonate in chronic cluster headache assessment of therapeutic efficacy and possible mechanisms of action. Ital J Neurol Sci. 1980 Jun;1(3):149-53. PubMed PMID: 6804412.

Miller H, Panahi L, Tapia D, Tran A, Bowman JD. Loperamide misuse and abuse. J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S): S45-S50. doi: 10.1016/j.japh.2016.12.079. Epub 2017 Feb 8. Review. PubMed PMID: 28189538.

Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992 Jan-Feb;14(1):17-21. PubMed PMID: 1349509.

Braun JJ, Alabert JP, Michel FB, Quiniou M, Rat C, Cougnard J, Czarlewski W, Bousquet J. Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. Allergy. 1997 Jun;52(6):650-5. PubMed PMID: 9226059.

Tanaka S, Hirata K, Kurihara N, Yoshikawa J, Takeda T. Effect of loratadine, an H1

antihistamine, on induced cough in non-asthmatic patients with chronic cough. Thorax. 1996 Aug;51(8):810-4. PubMed PMID: 8795669; PubMed Central PMCID: PMC472550.

van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol. 2003 Jul;30(7):1558-60. PubMed PMID: 12858458.

Vitek W, Alur S, Hoeger KM. Off-label drug use in the treatment of polycystic ovary syndrome. Fertil Steril. 2015 Mar;103(3):605-11. doi: 10.1016/j.fertnstert.2015.01.019. Review. PubMed PMID: 25726702.

Martins WP. Metformin for women with hyperandrogenic anovulation. Hum Reprod Update. 2016 Apr;22(3):406-7. doi: 10.1093/humupd/dmv064. Epub 2016 Feb 22. PubMed PMID: 26906093.

Codner E, Iñíguez G, López P, Mujica V, Eyzaguirre FC, Asenjo S, Torrealba I, Cassorla F. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr. 2013;80(5):343-9. doi: 10.1159/000355513. Epub 2013 Nov 6. PubMed PMID: 24280743.

Metformin in obesity. Arch Dis Child. 2014 Mar;99(3):231. doi: 10.1136/archdischild-2014-305957. PubMed PMID: 24526619.

El-Arabey AA. Update on off label use of metformin for obesity. Prim Care Diabetes. 2018 Jun;12(3):284-285. doi: 10.1016/j.pcd.2018.02.004. Epub 2018 Mar 7. PubMed PMID: 29525383.

Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, Barzilai A. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012 Jan-Feb;22(1):83-7. doi: 10.1684/ejd.2011.1611. PubMed PMID: 22266247.

Marret H, Fauconnier A, Dubernard G, Misme H, Lagarce L, Lesavre M, Fernandez H, Mimoun C, Tourette C, Curinier S, Rabishong B, Agostini A. Overview and guidelines of off-label use of methotrexate in ectopic pregnancy: report by CNGOF. Eur J Obstet Gynecol Reprod Biol. 2016 Oct; 205:105-9. doi: 10.1016/j.ejogrb.2016.07.489. Epub 2016 Aug 3. Review. PubMed PMID: 27572300.

Click JW, Qureshi AA, Vleugels RA. Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol. 2013 Jun;68(6):1043-5. doi: 10.1016/j.jaad.2013.01.008. PubMed PMID: 23680200.

Shah N, Alhusayen R, Walsh S, Shear NH. Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study [Formula: see text]. J Cutan Med Surg. 2018 Sep/Oct;22(5):484-487. doi: 10.1177/1203475418781336. Epub 2018 Jun 1. PubMed PMID: 29855201.

Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2018 Jul 9. pii: S0190-9622(18)32223-0. doi: 10.1016/j.jaad.2018.06.064. [Epub ahead of print] PubMed PMID: 30003990.

Foeldvari I. Methotrexate in juvenile localized scleroderma: adding to the evidence. Arthritis Rheum. 2011 Jul;63(7):1779-81. doi: 10.1002/art.30266. PubMed PMID: 21305527.

Parsad D, Pandhi R, Negi KS, Kumar B. Topical metronidazole in seborrheic dermatitis--a double-blind study. Dermatology. 2001;202(1):35-7. PubMed PMID: 11244226.

Schwale M, Frosch P, Tölle E, Niermann H. [Treatment of retrograde ejaculation and anorgasm with an alpha-sympathomimetic agent (Midodrin)]. Z Hautkr. 1980 Jun 1;55(11):756-9. German. PubMed PMID: 6158188.

Leduc BE, Fournier C, Jacquemin G, Lepage Y, Vinet B, Hétu PO, Chagnon M. Midodrine in patients with spinal cord injury and anejaculation: A double-blind randomized placebo-controlled pilot study. J Spinal Cord Med. 2015 Jan;38(1):57-62. doi: 10.1179/2045772314Y.0000000225. Epub 2014 Jun 26. PubMed PMID: 24969635; PubMed Central PMCID: PMC4293534.

Graupera I, Ginès P. Hepatorenal syndrome: The last pieces of the puzzle or not yet? Hepatology. 2015 Aug;62(2):352-4. doi: 10.1002/hep.27829. Epub 2015 May 29. PubMed PMID: 25846649.

Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015 Oct 20;(10):CD008244. doi:

10.1002/14651858.CD008244.pub3. Review. PubMed PMID: 26482422.

Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord. 2002 Dec;9(2):125-6. PubMed PMID: 12473405

Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol. 2017 Mar;31(3):327-337. doi: 10.1177/0269881116681399. Epub 2017 Jan 16. PubMed PMID: 28093029

Voigt F, Goecke TW, Najjari L, Pecks U, Maass N, Rath W. Off-label use of misoprostol for labor induction in Germany: a national survey. Eur J Obstet Gynecol Reprod Biol. 2015 Apr; 187: 85-9. doi: 10.1016/j.ejogrb.2014.11.026. Epub 2014 Dec 12. PubMed PMID: 25553610.

Garrigue A, Pierre F. [Misoprostol: off-label use in the treatment of post-partum hemorrhage]. J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):179-89. doi: 10.1016/j.jgyn.2013.11.011. Epub 2014 Jan 20. Review. French. PubMed PMID: 24457021.

Schaller JL, Behar D. Modafinil in fibromyalgia treatment. J Neuropsychiatry Clin Neurosci. 2001 Fall;13(4):530-1. PubMed PMID: 11748325.

Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, Han X, Dong Y. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013 Dec 3;8(12): e81802. doi: 10.1371/journal.pone.0081802. eCollection 2013. Review. PubMed PMID: 24312590; PubMed Central PMCID: PMC3849275.

Turkington D, Hedwat D, Rider I, Young AH. Recovery from chronic fatigue syndrome with modafinil. Hum Psychopharmacol. 2004 Jan;19(1):63-4. PubMed PMID: 14716715.

McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM. The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017 Aug;37(4):412-418. doi: 10.1097/JCP.0000000000000723. Review. PubMed PMID: 28590365

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. J Psychiatr Res. 2017 Jan; 84: 292-300. doi: 10.1016/j.jpsychires.2016.09.034. Epub 2016 Oct 20. PubMed PMID: 27810669.

Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD--a preliminary observation. Respir Med. 2004 Feb;98(2):134-8. PubMed PMID: 14971876.

Jeon YH, Min TK, Yang HJ, Pyun BY. A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children. Allergy Asthma Immunol Res. 2016 Jul;8(4):305-11. doi: 10.4168/aair.2016.8.4.305. PubMed PMID: 27126723; PubMed Central PMCID: PMC4853507.

Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9):611-34. Review. PubMed PMID: 12153333.

Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005 Sep;297(3):134-8. Epub 2005 Sep 29. PubMed PMID: 16044256.

Thee S, Garcia-Prats AJ, Draper HR, McIlleron HM, Wiesner L, Castel S, Schaaf HS, Hesseling AC. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis. 2015 Feb 15;60(4):549-56. doi: 10.1093/cid/ciu868. Epub 2014 Oct 30. PubMed PMID: 25362206; PubMed Central PMCID: PMC4366580.

Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet. 1997 Oct 4;350(9083):1003-4. PubMed PMID: 9329520.

Mimura T, Kanda H, Kubo K. [Treatment of steroid-resistant polymyositis and dermatomyositis]. Nihon Rinsho. 2001 Oct;59(10):2062-70. Review. Japanese. PubMed PMID: 11676154.

Sepe V, Libetta C, Giuliano MG, Adamo G, Dal Canton A. Mycophenolate mofetil in primary glomerulopathies. Kidney Int. 2008 Jan;73(2):154-62. Epub 2007 Nov 7. Review. PubMed PMID: 17989649.

Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, Truglia S, Miranda F, Morello F, Alessandri C, Spinelli FR, Valesini G. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Immunol Res. 2014 Dec;60(2-3):270-6. doi: 10.1007/s12026-014-8609-x. Review. PubMed PMID: 25468307.

Hobson-Webb LD, Hehir M, Crum B, Visser A, Sanders D, Burns TM. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle Nerve. 2015 Aug;52(2):211-5. doi: 10.1002/mus.24694. Epub 2015 Jun 18. PubMed PMID: 25906756.

Doukaki S, Platamone A, Alaimo R, Bongiorno MR. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Dermatolog Treat. 2015 Feb;26(1):67-72. doi: 10.3109/09546634.2014.880395. Epub 2014 Feb 13. Review. PubMed PMID: 24521072.

Mertens JS, Marsman D, van de Kerkhof PC, Hoppenreijs EP, Knaapen HK, Radstake TR, de Jong EM, Seyger MM. Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. Acta Derm Venereol. 2016 May;96(4):510-3. doi: 10.2340/00015555-2297. PubMed PMID:26582717.

Xiao Y, Huang J, Luo H, Wang J. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014 Feb 7;(2):CD010242. doi: 10.1002/14651858.CD010242.pub2. Review. PubMed PMID: 24505016.

Yasuda S, Atsumi T, Shimamura S, Ono K, Hiromura K, Sada K, Mori M, Takei S, Kawaguchi Y, Tamura N, Takasaki Y. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. Mod Rheumatol. 2015;25(6):854-7. doi: 10.3109/14397595.2015.1031444. Epub 2015 Apr 30. PubMed PMID: 25800636.

Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002 Mar;61(3):1098-114. PubMed PMID: 11849465.

Gracia-Naya M, Huerta-Villanueva M, Ríos-Gómez C, Latorre-Jiménez AM, Sánchez-Valiente S, Santos-Lasaosa S, Mauri-Llerda JA, García-Gómara MJ, Artal-Roy J. [Comparative study of the effectiveness of topiramate and nadolol in the preventive treatment of episodic migraine in independent series of patients]. Rev Neurol. 2010 May 1;50(9):513-9. Spanish. PubMed PMID: 20443169.

Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med. 2014 May;15(5):883-4. PubMed PMID: 24967470.

Beach MA, Mauro LS. Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1361-8. Epub 2006 Jul 18. Review. PubMed PMID:16849614.

Parant O, Deudon R, Bennevent J, Viard C, Damase-Michel C, Guyard-Boileau B. [Use of calcium channel blockers (CCB) for tocolysis in France and abroad]. J Gynecol Obstet Biol Reprod (Paris). 2015 Apr;44(4):312-23. doi: 10.1016/j.jgyn.2014.12.016. Epub 2015 Feb 26. Review. French. PubMed PMID: 25728784.

Rosen CA, Smith L, Young V, Krishna P, Muldoon MF, Munin MC. Prospective investigation of nimodipine for acute vocal fold paralysis. Muscle Nerve. 2014 Jul;50(1):114-8. doi: 10.1002/mus.24111. Epub 2014 May 5. PubMed PMID: 24639294.

Scheller K, Scheller C. Nimodipine promotes regeneration of peripheral facial nerve function after traumatic injury following maxillofacial surgery: an off- label pilot-study. J Craniomaxillofac Surg. 2012 Jul;40(5):427-34. doi: 10.1016/j.jcms.2011.07.016. Epub 2011 Sep 1. PubMed PMID: 21885293.

Mamdani H, Wu H, O'Neil BH, Sehdev A. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature. Discov Med. 2017 May;23(128):331-336. Review. PubMed PMID: 28715649.

Scarpignato C. The place of octreotide in the medical management of the dumping syndrome. Digestion. 1996;57 Suppl 1:114-8. Review. PubMed PMID: 8813487.

Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary

aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol. 2014 May;49(5):503-7. doi: 10.1002/ppul.22937. Epub 2013 Oct 25. Review. PubMed PMID: 24167019.

Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S, Suárez Fernández R. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012 Sep;103(7):624-8. Epub 2011 Nov 3. English, Spanish. PubMed PMID: 22056257.

Lieberman JA, Chehade M. Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep. 2013 Feb;13(1):78-84. doi: 10.1007/s11882-012-0316-x. Review. PubMed PMID: 23065311.

Occasi F, Duse M, Nebbioso M, De Castro G, Di Fraia M, Capata G, Lollobrigida V, Zicari AM. Vernal keratoconjunctivitis treated with omalizumab: A case series. Pediatr Allergy Immunol. 2017 Aug;28(5):503-505. doi: 10.1111/pai.12737. PubMed PMID: 28543949.

Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, Siebenhaar F, Møller MB, Kristensen TK, Bindslev-Jensen C; Mastocytosis Centre Odense University Hospital (MastOUH). Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27. PubMed PMID: 28662309.

Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014 Sep;71(3):468-74. doi: 10.1016/j.jaad.2014.04.053. Epub 2014 Jun 20. PubMed PMID: 24954907.

Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011 Sep;66(9):824-5. doi: 10.1136/thx.2010.152835. Epub 2010 Nov 25. PubMed PMID: 21109700.

Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther. 2013 Jun;13(6):933-45. doi: 10.1517/14712598.2013.795943. Epub 2013 Apr 29. Review. PubMed PMID: 23621175.

Chularojanamontri L, Wimoolchart S, Tuchinda P, Kulthanan K, Kiewjoy N. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol. 2009 Dec;27(4):233-6. PubMed PMID: 20232578.

Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007963. doi: 10.1002/14651858.CD007963.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Dec 02;12: CD007963. PubMed PMID: 23543558.

Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014 Jun 9; 15: 34. doi: 10.1186/1129-2377-15-34. PubMed PMID: 24912658; PubMed Central PMCID: PMC4067104.

Caputo F, Vignoli T, Tarli C, Domenicali M, Zoli G, Bernardi M, Addolorato G. A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder. Int J Environ Res Public Health. 2016 Mar 5;13(3). pii: E290. doi: 10.3390/ijerph13030290. Review. PubMed PMID: 26959045; PubMed Central PMCID: PMC4808953.

Leu-Semenescu S, Louis P, Arnulf I. Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. Sleep Med. 2016 Jan; 17: 38-44. doi: 10.1016/j.sleep.2015.10.005. Epub 2015 Oct 19. PubMed PMID: 26847972.

Campanati A, Gregoriou S, Kontochristopoulos G, Offidani A. Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art. Skin Appendage Disord. 2015 Mar;1(1):6-13. doi: 10.1159/000371581. Epub 2015 Jan 30. Review. PubMed PMID: 27172124; PubMed Central PMCID: PMC4857824.

Kubalek I, Fain O, Paries J, Kettaneh A, Thomas M. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford). 2001 Dec;40(12):1394-7. PubMed PMID: 11752511.

Swaiman KF, Flagler DG. Mercury poisoning with central and peripheral nervous system involvement

treated with penicillamine. Pediatrics. 1971 Oct;48(4):639-42. PubMed PMID: 5165505.

Chehab M, Madala A, Trussell JC. On-label and off-label drugs used in the treatment of male infertility. Fertil Steril. 2015 Mar;103(3):595-604. doi: 10.1016/j.fertnstert.2014.12.122. Epub 2015 Feb 3. Review. PubMed PMID: 25660648.

Chan GM, Sharma R, Price D, Hoffman RS, Nelson LS. Phentolamine therapy for cocaine-association acute coronary syndrome (CAACS). J Med Toxicol. 2006 Sep;2(3):108-11. PubMed PMID: 18072128; PubMed Central PMCID: PMC3550159.

Evidente VG. Piribedil for restless legs syndrome: a pilot study. Mov Disord. 2001 May;16(3):579-81. PubMed PMID: 11391766.

Leu-Semenescu S, Nittur N, Golmard JL, Arnulf I. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med. 2014 Jun;15(6):681-7. doi: 10.1016/j.sleep.2014.01.021. Epub 2014 Mar 18. PubMed PMID: 24854887.

Roberge RJ, Martin TG, Schneider SM. Use of sodium polystyrene sulfonate in a lithium overdose. Ann Emerg Med. 1993 Dec;22(12):1911-5. PubMed PMID: 8239115.

Tomaszewski C, Musso C, Pearson JR, Kulig K, Marx JA. Lithium absorption prevented by sodium polystyrene sulfonate in volunteers. Ann Emerg Med. 1992 Nov;21(11):1308-11. PubMed PMID: 1416323.

Harten P. [Fibromyalgia syndrome: new developments in pharmacotherapy]. Z Rheumatol. 2008 Feb;67(1):75-82. Review. German. PubMed PMID: 17924124.

Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. J Reprod Immunol. 2017 Nov; 124: 15-20. doi: 10.1016/j.jri.2017.09.009. Epub 2017 Sep 29. Review. PubMed PMID: 29028516.

Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D'Alton M, Hankins G; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016 Jun;214(6): 720.e1-720.e17. doi: 10.1016/j.ajog.2015.12.038. Epub 2015 Dec 23. PubMed PMID: 26723196; PubMed Central PMCID: PMC4884459.

Giladi H, Choinière M, Fitzcharles MA, Ware MA, Tan X, Shir Y. Pregabalin for chronic pain: does one medication fit all? Curr Med Res Opin. 2015;31(7):1403-11. doi: 10.1185/03007995.2015.1040750. Epub 2015 May 11. PubMed PMID: 25868712.

Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology. 1986 Jan;36(1):121-4. PubMed PMID: 3941767.

Amin DN, Henry JA. Propranolol administration in theophylline overdose. Lancet. 1985 Mar 2;1(8427):520-1. PubMed PMID: 2857884.

Evreux JC, Motin J, Vincent V, Faucon G. [Testing of propranolol atainst cardiac arrhythmia from experimental trichloroethylese intoxication]. Med Pharmacol Exp Int J Exp Med. 1967;17(6):527-33. French. PubMed PMID: 5631689.

Wenkstern AR, Petersen H. Intravitreal ranibizumab in retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1667-70. doi: 10.1007/s00417-010-1380-3. Epub 2010 May 28. PubMed PMID: 20508944.

Kamar N, Mallet V, Izopet J. Ribavirin for chronic hepatitis E virus infection. N Engl J Med. 2014 Jun 19;370(25):2447-8. doi: 10.1056/NEJMc1405191. PubMed PMID: 24941183.

Bomm L, Fracaroli TS, Sodré JL, Bressan A, Gripp AC. Off-label use of rituximab in dermatology: pemphigus treatment. An Bras Dermatol. 2013 Jul-Aug;88(4):676-8. doi: 10.1590/abd1806-4841.20131905. PubMed PMID: 24068154; PubMed Central PMCID: PMC3760958.

Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, Govoni M, Gremese E, Iuliano A, Mansutti E, Moroni G, Mosca M, Nalli C, Naretto C, Padovan M, Palma L, Raffiotta F, Roccatello D, Tincani A, Valesini G, Zen M, Doria A. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015

Jul-Aug;33(4):449-56. Epub 2015 Jun 8. PubMed PMID: 26053285.

Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood. 2015 May 21;125(21):3223-9. doi: 10.1182/blood-2015-01-588392. Epub 2015 Mar 31. Review. PubMed PMID: 25827833.

Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005 Jul;64(7):1099-100. Review. PubMed PMID: 15958774; PubMed Central PMCID: PMC1755553.

Sakamoto AP, Pinheiro MM, Barbosa CM, Fraga MM, Len CA, Terreri MT. Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. Rev Bras Reumatol. 2015 Nov-Dec;55(6):536-41. doi: 10.1016/j.rbr.2014.12.015. Epub 2015 May 26. English, Portuguese. PubMed PMID: 26066294.

Unger L, Kampf S, Lüthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014 Sep;53(9):1630-8. doi: 10.1093/rheumatology/keu024. Epub 2014 Apr 4. PubMed PMID: 24706995.

Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012 May;39(5):477-9. Review. PubMed PMID: 22611565.

Makhdoomi K, Abkhiz S, Noroozinia F, Mivefroshan A, Zeinali J, Jafari L, Jafari L, Saffarifard A. Recurrent idiopathic membranous glomerulonephritis after kidney transplantation and successful treatment with rituximab. Iran J Kidney Dis. 2015 Mar;9(2):158-62. PubMed PMID: 25851296.

Makhdoomi K, Abkhiz S, Noroozinia F, Mivefroshan A, Zeinali J, Jafari L, Jafari L, Saffarifard A. Recurrent idiopathic membranous glomerulonephritis after kidney transplantation and successful treatment with rituximab. Iran J Kidney Dis. 2015 Mar;9(2):158-62. PubMed PMID: 25851296.

Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A. Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7. PubMed PMID: 25195120.

Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637-42. doi: 10.3109/10428194.2015.1012714. Epub 2015 Mar 14. PubMed PMID: 25651423.

Tello-Winniczuk N, Díaz-Jouanen E. [Rituximab: a new therapeutic alternative in Grave's disease]. Rev Invest Clin. 2011 Sep-Oct;63(5):536-43. Spanish. PubMed PMID: 22468483.

Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves'orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. doi: 10.1210/jc.2014-3014. Epub 2014 Dec 15. PubMed PMID: 25494967; PubMed Central PMCID: PMC4318899.

Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285-9. Epub 2003 Feb 13. PubMed PMID: 12586628.

Berentsen S. How I manage cold agglutinin disease. Br J Haematol. 2011 May;153(3):309-17. doi: 10.1111/j.1365-2141.2011.08643.x. Epub 2011 Mar 8. Review. PubMed PMID: 21385173.

Syeda UA, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review. Semin Arthritis Rheum. 2013 Jun;42(6):567-72. doi: 10.1016/j.semarthrit.2012.10.007. Epub 2013 Jan 24. Review. PubMed PMID: 23352254.

Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a

systematic review and meta-analysis. J Neurol. 2015 May;262(5):1115-9. doi: 10.1007/s00415-014-7532-3. Epub 2014 Oct 12. Review. PubMed PMID: 25308632.

Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, Ruiz-Ramos J, Alcalá-Vicente C, Poveda-Andrés JL. Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia. 2015 Oct;30(8):461-4. doi: 10.1016/j.nrl.2014.09.001. Epub 2014 Nov 11. English, Spanish. PubMed PMID: 25444411.

Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol. 2013 Aug;69(2):310-1. doi: 10.1016/j.jaad.2013.01.046. PubMed PMID: 23866864.

Shetty S, Ahmed AR. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol. 2013 Jun 1;12(6):672-7. Review. PubMed PMID: 23839185.

Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007 Jan 2;146(1):25-33. Review. PubMed PMID: 17200219.

Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013 Mar;11(3):481-90. doi: 10.1111/jth.12114. PubMed PMID: 23279219.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review. PubMed PMID: 24310855.

Souza FB, Porfírio GJ, Andriolo BN, Albuquerque JV, Trevisani VF. Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis. PLoS One. 2016 Mar 21;11(3):e0150749. doi: 10.1371/journal.pone.0150749. eCollection 2016. Review. PubMed PMID: 26998607; PubMed Central PMCID: PMC4801187.

Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, Jungbluth H, Robb S, Hilton-Jones D. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):671-3. doi: 10.1136/jnnp.2009.197632. Epub 2010 Apr 14. PubMed PMID: 20392977.

Keijzer-Veen MG, Hebert D, Parekh RS; INSIGHT group. Rituximab for patients with nephrotic syndrome. Lancet. 2015 Jan 17;385(9964):225. doi: 10.1016/S0140-6736(15)60049-6. PubMed PMID: 25706701.

Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K. Single-dose rituximab in refractory lupus nephritis. Intern Med J. 2016 Aug;46(8):899-901. doi: 10.1111/imj.13136. PubMed PMID: 27242250

Sagiv O, Thakar SD, Morrell G, Tetzlaff MT, Esmaeli B. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. Ophthalmic Plast Reconstr Surg. 2018 Jan/Feb;34(1): e24-e27. doi: 10.1097/IOP.0000000000000988. PubMed PMID: 28863117.

Tassinari D, Poggi B, Fantini M, Tamburini E, Sartori S. Treating sialorrhea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients. Support Care Cancer. 2005 Jul;13(7):559-61. Epub 2005 Apr 30. PubMed PMID: 15864657.

Giovannoni G, Baker D, Schmierer K. Simvastatin in patients with progressive multiple sclerosis. Lancet. 2014 Sep 13;384(9947):952. doi: 10.1016/S0140-6736(14)61621-4. PubMed PMID: 25220965.

Miano M, Calvillo M, Palmisani E, Fioredda F, Micalizzi C, Svahn J, Banov L, Russo G, Lanza T, Dufour C. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014 Nov;167(4):571-4. doi: 10.1111/bjh.13010. Epub 2014 Jun 30. PubMed PMID: 24975111.

Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol. 2016 Jun 21;22(23):5400-5. doi: 10.3748/wjg.v22.i23.5400.

PubMed PMID: 27340356; PubMed Central PMCID: PMC4911348.

Salavastru CM, Fritz K, Tiplica GS. [Spironolactone in dermatological treatment. On and off label indications]. Hautarzt. 2013 Oct;64(10):762-7. doi: 10.1007/s00105-013-2597-y. German. PubMed PMID: 24150826.

Milewicz A, Grabiński M, Tupikowska G, Szymczak J. [Use of spironolactone in the treatment of women with polycystic ovary syndrome associated with hyperprolactinemia]. Ginekol Pol. 1984 Oct;55(10):737-40. Polish. PubMed PMID:6534800

Intong LR, Murrell DF. Management of epidermolysis bullosa acquisita. Dermatol Clin. 2011 Oct;29(4):643-7. doi: 10.1016/j.det.2011.06.020. Epub 2011 Aug 15. Review. PubMed PMID: 21925011.

Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014 Nov 27;(11):CD004800. doi: 10.1002/14651858.CD004800.pub3. Review. PubMed PMID: 25427435.

Sturt NJ, Phillips RK, Clark SK. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004 Aug 1;101(3):652; author reply 653. PubMed PMID: 15274082.

Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin. 2010 Jul;28(3):535-45. doi: 10.1016/j.det.2010.03.008. Review. PubMed PMID: 20510763.

Hengge UR. [Off-label indications for topical tacrolimus]. Hautarzt. 2013 Oct;64(10):752-6. doi: 10.1007/s00105-013-2594-1. German. PubMed PMID: 24150824.

Matsubara S, Kondo K, Sugaya K, Miyamoto K. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol. 2012 Oct;31(10):1493-8. doi: 10.1007/s10067-012-2044-y. Epub 2012 Aug 12. Review. PubMed PMID: 22886003.

Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013 Jun;19(7):1490-8. doi: 10.1097/MIB.0b013e318281f362. PubMed PMID: 23615528.

Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z, Chen J, Fu J, Zhang J, Kong Y, Fu P, Lou T, Liu Z, Yu X, Chen W. Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol. 2013 Apr;45(2):459-68. doi: 10.1007/s11255-012-0205-1. Epub 2012 Jun 9. PubMed PMID: 22684795.

Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. J Pediatr Endocrinol Metab. 2013;26(9-10):803-7. doi: 10.1515/jpem-2013-0052. Review. PubMed PMID: 23729603

Shokeir TA. Tamoxifen citrate for women with unexplained infertility. Arch Gynecol Obstet. 2006 Aug;274(5):279-83. Epub 2006 Jun 8. PubMed PMID: 16847636.

Malo C, Audette-Côté JS, Emond M, Turgeon AF. Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and meta-analysis. CJEM. 2014 May;16(3):229-42. Review. PubMed PMID: 24852587.

Chen K, Mi H, Xu G, Liu L, Sun X, Wang S, Meng Q, Lv T. The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Endourol. 2015 Oct;29(10):1166-76. doi: 10.1089/end.2015.0098. Epub 2015 Jun 17. Review. PubMed PMID: 25915454.

Campione E, Paternò EJ, Costanza G, Diluvio L, Carboni I, Marino D, Favalli C, Chimenti S, Bianchi L, Orlandi A. Tazarotene as alternative topical treatment for onychomycosis. Drug Des Devel Ther. 2015 Feb 16; 9: 879-86. doi: 10.2147/DDDT.S69946. eCollection 2015. PubMed PMID: 25733808; PubMed Central PMCID: PMC4338256.

Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Epub 2010 Sep 15. Review. PubMed PMID: 20845485.

Añón AO, Porta MM, López CQ, Hanzu FA, Rabinovich IH. Treatment of unresponsive hypoparathyroidism when the oral route administration is not possible: considering

subcutaneous teriparatide. Endocrinol Nutr. 2015 Aug-Sep;62(7):361-2. doi: 10.1016/j.endonu.2015.03.006. Epub 2015 May 8. PubMed PMID: 25959089.

Doh RM, Park HJ, Rhee Y, Kim HS, Huh J, Park W. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants. Implant Dent. 2015 Apr;24(2):222-6. doi: 10.1097/ID.0000000000000232. PubMed PMID: 25734949.

Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28(7):443-59. Review. PubMed PMID: 18544005.

Moon SE, Hwang EJ, Cho KH. Treatment of pyogenic granuloma by sodium tetradecyl sulfate sclerotherapy. Arch Dermatol. 2005 May;141(5):644-6. PubMed PMID: 15897398.

Agarwal S. Treatment of oral hemangioma with 3% sodium tetradecyl sulfate: study of 20 cases. Indian J Otolaryngol Head Neck Surg. 2012 Sep;64(3):205-7. doi: 10.1007/s12070-011-0249-z. Epub 2011 Apr 13. PubMed PMID: 23998020; PubMed Central PMCID: PMC3431531.

Kim JY, Kim JS, Kim MH, Park BC, Hong SP. Intralesional 3% sodium tetradecyl sulfate for treatment of cutaneous Kaposi's sarcoma. Yonsei Med J. 2015 Jan;56(1):307-8. doi: 10.3349/ymj.2015.56.1.307. PubMed PMID: 25510781; PubMed Central PMCID: PMC4276773.

Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin. 2010 Jul;28(3):577-86. doi: 10.1016/j.det.2010.03.003. Review. PubMed PMID: 20510766.

Moura AK, Moure ER, Romiti R. Treatment of cutaneous lichen planus with thalidomide. Clin Exp Dermatol. 2009 Jan;34(1):101-3. doi: 10.1111/j.1365-2230.2008.03046.x. PubMed PMID: 19076811.

Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016 Oct 28;22(40):9012-9021. Review. PubMed PMID: 27833392; PubMed Central PMCID: PMC5083806.

Madureira P, Pimenta SS, Bernardo A, Brito JS, Bernardes M, Costa L. Off-label Use of Tocilizumab in Psoriatic Arthritis: Case Series and Review of the Literature. Acta Reumatol Port. 2016 Jul-Sep;41(3):251-255. Review. PMID: 27155213.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542-52. DOI: 10.1002/art.27221 PMID: 20112381 PMCID: PMC3057537.

Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A. Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunol Res. 2013 Jul;56(2-3):390-7. doi: 10.1007/s12026-013-8411-1. Review. PMID: 23572430.

Nagai K, Ueda A, Yamagata K. Successful use of tocilizumab in a case of multicentric Castleman's disease and end-stage renal disease. Ther Apher Dial. 2014 Apr;18(2):210-1. doi: 10.1111/1744-9987.12128. Epub 2013 Oct 31. PMID: 24571441.

Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford). 2018 Feb 1;57(2):398-401. doi: 10.1093/rheumatology/kex382. PubMed PMID: 29077971.

Guardia D, Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. Supervised off-label prescribing of topiramate for binge eating disorder within the system CAMTEA.Therapie. 2012 Sep-Oct;67(5):480-1. doi: 10.2515/therapie/2012063. Epub 2012 Dec 18.

Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Review. PubMed PMID: 27902848.

Steffen A, Hasselbacher K, Brüggemann N, Heinrichs S, Schönweiler R, Wollenberg B. [Botulinum Toxin in Functional Hypersalivation--All about Dosage?]. Laryngorhinootologie. 2015 Jun;94(6):378-82. doi: 10.1055/s-0034-1394376. Epub 2014 Dec 1. German. PubMed PMID: 25437838.

Moga MA, Banciu S, Dimienescu O, Bigiu NF, Scarneciu I. Botulinum-A Toxin's efficacy in the treatment of idiopathic overactive bladder. J Pak Med Assoc. 2015 Jan;65(1):76-80. Review. PubMed PMID: 25831681.

Colosimo C, Chianese M, Giovannelli M, Contarino MF, Bentivoglio AR. Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol Neurosurg Psychiatry. 2003 May;74(5):687. PubMed PMID: 12700325; PubMed Central PMCID: PMC1738417.

Sataloff RT, Heman-Ackah YD, Simpson LL, Park JB, Zwislewski A, Sokolow C, Mandel S. Botulinum toxin type B for treatment of spasmodic dysphonia: a case report. J Voice. 2002 Sep;16(3):422-4. PubMed PMID: 12395995.

Nelson L, Bachoo P, Holmes J. Botulinum toxin type B: a new therapy for axillary hyperhidrosis. Br J Plast Surg. 2005 Mar;58(2):228-32. PubMed PMID: 15710119.

Colosimo C, Chianese M, Giovannelli M, Contarino MF, Bentivoglio AR. Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol Neurosurg Psychiatry. 2003 May;74(5):687. PubMed PMID: 12700325; PubMed Central PMCID: PMC1738417.

Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003 Jan;84(1):103-7. PubMed PMID: 12589629.

Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotox Res. 2006 Apr;9(2-3):173-7. Review. PubMed PMID: 16785115.

Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. 2013 Jul;156(1):173-177.e2. doi: 10.1016/j.ajo.2013.02.001. Epub 2013 Mar 28. PubMed PMID: 23541393.

Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Dec;14(6):424-6. Epub 2003 Nov 25. PubMed PMID: 14677005.

Sadick NS. The cosmetic use of botulinum toxin type B in the upper face. Clin Dermatol. 2004 Jan-Feb;22(1):29-33. Review. PubMed PMID: 15158542.

Kumral TL, Yıldırım G, Berkiten G, Saltürk Z, Ataç E, Atar Y, Uyar Y. Efficacy of Trimetazidine Dihydrochloride for Relieving Chronic Tinnitus: A Randomized Double-Blind Study. Clin Exp Otorhinolaryngol. 2016 Sep;9(3):192-7. doi: 10.21053/ceo.2015.00619. Epub 2016 May 27. PubMed PMID: 27230273; PubMed Central PMCID: PMC4996095.

Bouccara D. [Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials]. Ann Otolaryngol Chir Cervicofac. 1999 Apr;116(1):43-6. Review. French. PubMed PMID: 10367069.

Kozakiewicz K, Petelenz T, Chruściel TL. [Effectiveness of trimetazidine in patients with hypertension and the symptoms of coronary disease]. Pol Tyg Lek. 1992 Jul 6-13;47(27-28):594-6. Polish. PubMed PMID: 1488335.

Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol. 2010 Sep-Oct;20(5):630-1. doi: 10.1684/ejd.2010.1004. Epub 2010 Jul 7. PubMed PMID: 20605773.

Montoya JG1, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, Watt T, Kubo JT, Paik J, Desai M. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol. 2013 Dec;85(12):2101-9. doi: 10.1002/jmv.23713. Epub 2013 Aug 19. PMID: 23959519.

Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2014 Aug;20(4):257-62. doi: 10.1177/1078155213501360. Epub 2013 Sep 9. PMID: 24022408.

Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K,

Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599. PMID: 25738669 PMCID: PMC4401811.

Soyka M, Müller CA. Pharmacotherapy of alcoholism - an update on approved and off-label medications. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24. Review. PubMed PMID: 28658981.

Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015 Jul;152(2):231-7. doi: 10.1007/s10549-015-3465-5. Epub 2015 Jun 12. Review. PubMed PMID: 26067931.

Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Aug 23;(8):CD011091. doi: 10.1002/14651858.CD011091.pub2. Review. PubMed PMID: 26298465

Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. Review. PubMed PMID: 19125880.

Nguyen ML, Pirzada MH, Shapiro MA. Zonisamide for weight loss in adolescents. J Pediatr Pharmacol Ther. 2013 Oct;18(4):311-4. doi: 10.5863/1551-6776-18.4.311. PubMed PMID: 24719592; PubMed Central PMCID: PMC3979054.

http://www.ophtalmologie-lariboisiere.fr/documents/fiches/Info%20IVT%20Kenacort.pdf.

Morioka M, Takamura Y, Yamada Y, Matsumura T, Gozawa M, Inatani M. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2018 Dec;256(12):2301-2307. doi: 10.1007/s00417-018-4141-3. Epub 2018 Sep 20. PubMed PMID: 30238189.

Ogura Y, Shimura M, Iida T, Sakamoto T, Yoshimura N, Yamada M, Ishibashi T. Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. Ophthalmologica. 2019;241(3):161-169. doi: 10.1159/000492135. Epub 2018 Sep 3. PubMed PMID: 30176671.

Prager SG, Lammer J, Mitsch C, Hafner J, Pemp B, Scholda C, Kundi M, Schmidt-Erfurth U, Kriechbaum K. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab

or triamcinolone. Acta Ophthalmol. 2018 Mar; 96(2): e195-e200. Doi :10.1111/aos.13520. Epub 2017 Oct 24. PubMed PMID: 29063703.

Yu SY, Nam DH, Lee DY. Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):39-47. doi: 10.1007/s00417-017-3819-2. Epub 2017 Oct 13. PubMed PMID: 29030692.

Zając-Pytrus HM, Kaczmarek R, Strońska-Lipowicz D, Pomorska M, Misiuk-Hojło M. The effects and safety of intravitreal triamcinolone injections in the treatment of diabetic macular edema. Adv Clin Exp Med. 2017 Jan-Feb;26(1):45-49. doi: 10.17219/acem/29849. PubMed PMID: 28397431.

Lim LL, Morrison JL, Constantinou M, Rogers S, Sandhu SS, Wickremasinghe SS, Kawasaki R, Al-Qureshi S. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of

cataract surgery - preliminary 6 month results. Clin Exp Ophthalmol. 2016 May;44(4):233-42. doi: 10.1111/ceo.12720. Epub 2016 Mar 29. PubMed PMID: 26871700.

Riazi-Esfahani M, Riazi-Esfahani H, Ahmadraji A, Karkhaneh R, Mahmoudi A, Roohipoor R, Ghasemi F, Yaseri M. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. Int Ophthalmol. 2018 Apr;38(2):585-598. doi: 10.1007/s10792-017-0496-4. Epub 2017 Mar 27. PubMed PMID: 28349504.

Lattanzio R, Cicinelli MV, Bandello F. Intravitreal Steroids in Diabetic Macular Edema. Dev Ophthalmol. 2017; 60: 78-90. doi: 10.1159/000459691. Epub 2017 Apr 20. Review. PubMed PMID: 28427068.

Yang Y, Bailey C, Loewenstein A, Massin P. INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS. Retina. 2015 Dec;35(12):2440-9. doi: 10.1097/IAE.0000000000000726. Review. PubMed PMID: 26352555; PubMed Central PMCID: PMC4697357.

Dedania VS, Bakri SJ. Novel pharmacotherapies in diabetic retinopathy. Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):164-73. doi: 10.4103/0974-9233.154389. Review. PubMed PMID: 25949073; PubMed Central PMCID: PMC4411612.

Jin E, Luo L, Bai Y, Zhao M. Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother. 2015 Apr;49(4):387-97. doi: 10.1177/1060028014568006. Epub 2015 Jan 26. Review. PubMed PMID: 25622852.

Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52(2):89-96. doi: 10.1159/000362764. Epub 2014 Aug 29. Review. PubMed PMID: 25195600.

Kumral TL, Yıldırım G, Berkiten G, Saltürk Z, Ataç E, Atar Y, Uyar Y. Efficacy of Trimetazidine Dihydrochloride for Relieving Chronic Tinnitus: A Randomized Double-Blind Study. Clin Exp Otorhinolaryngol. 2016 Sep;9(3):192-7. doi:

10.21053/ceo.2015.00619. Epub 2016 May 27. PubMed PMID: 27230273; PubMed Central PMCID: PMC4996095.

Bouccara D. [Contribution of vastarel 20 mg (trimetazidine) in the treatment of vertigo: synopsis of clinical trials]. Ann Otolaryngol Chir Cervicofac. 1999 Apr;116(1):43-6. Review. French. PubMed PMID: 10367069.

Kozakiewicz K, Petelenz T, Chruściel TL. [Effectiveness of trimetazidine in patients with hypertension and the symptoms of coronary disease]. Pol Tyg Lek. 1992 Jul 6-13;47(27-28):594-6. Polish. PubMed PMID: 1488335.

Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol. 2010 Sep-Oct;20(5):630-1. doi: 10.1684/ejd.2010.1004. Epub 2010 Jul 7. PubMed PMID: 20605773.

Montoya JG1, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, Watt T, Kubo JT, Paik J, Desai M. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol. 2013 Dec;85(12):2101-9. doi: 10.1002/jmv.23713. Epub 2013 Aug 19. PMID: 23959519.

Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2014 Aug;20(4):257-62. doi: 10.1177/1078155213501360. Epub 2013 Sep 9. PMID: 24022408.

Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008 Aug;33(9):2187-99. Epub 2007 Nov 14. PubMed PMID: 18004285.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23. PubMed PMID: 18436195.

Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F, Copolov DL, Bush AI. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. J Clin Psychiatry. 2011 Jul;72(7):909-13. doi: 10.4088/JCP.09m05741yel. Epub 2010 Sep 21. PubMed PMID: 20868637.

Carmeli C, Knyazeva MG, Cuénod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One. 2012;7(2): e29341. doi: 10.1371/journal.pone.0029341. Epub 2012 Feb 22. PubMed PMID: 22383949; PubMed Central PMCID: PMC3285150.

Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001. PubMed PMID: 24201233.

Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3; 57: 69-75. doi: 10.1016/j.pnpbp.2014.10.002. Epub 2014 Oct 12. PubMed PMID: 25315856.

Rossell SL, Francis PS, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean O, Liu D, Meyer D, Neill E, Phillipou A, Sarris J, Castle DJ. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo-controlled trial targeting negative symptoms. BMC Psychiatry. 2016 Sep 15;16(1):320. doi: 10.1186/s12888-016-1030-3. PubMed PMID: 27629871; PubMed Central PMCID: PMC5024434.

Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2; 82: 289-296. doi: 10.1016/j.pnpbp.2017.11.001. Epub 2017 Nov 7. PubMed PMID: 29126981.

Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y, Francis MM. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018 Sep; 199: 395-402. doi: 10.1016/j.schres.2018.03.012. Epub 2018 Mar 24. PubMed PMID: 29588126.

Klauser P, Xin L, Fournier M, Griffa A, Cleusix M, Jenni R, Cuenod M, Gruetter R, Hagmann P, Conus P, Baumann PS, Do KQ. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. Transl Psychiatry. 2018 Oct 12;8(1):220. doi: 10.1038/s41398-018-0266-8. PubMed PMID: 30315150; PubMed Central PMCID: PMC6185923.

Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abuse Treat. 2015 May; 52: 24-30. doi: 10.1016/j.jsat.2014.11.007. Epub 2014 Dec 2. PubMed PMID: 25572706.

Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. Alcohol Alcohol. 2014 Nov;49(6):654-60. doi: 10.1093/alcalc/agu062. Epub 2014 Sep 21. PubMed PMID: 25246489; PubMed Central PMCID: PMC4804107.

Reddy VK, Girish K, Lakshmi P, Vijendra R, Kumar A, Harsha R. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol. 2014 Jul-Aug;46(4):372-7. doi: 10.4103/0253-7613.135947. PubMed PMID: 25097273; PubMed Central PMCID: PMC4118528.

Geisel O, Schlemm L, Hellweg R, Wiedemann K, Müller CA. Hypothalamic-Pituitary-Adrenocortical Axis Activity in Alcohol-Dependent Patients During Treatment with High-Dose Baclofen. Pharmacopsychiatry. 2019 Jan;52(1):32-37. doi: 10.1055/s-0043-124189. Epub 2018 Jan 22. PubMed PMID: 29359279.

Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M. A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. Alcohol Alcohol. 2017 Jul 1;52(4):439-446. doi: 10.1093/alcalc/agx030. PubMed PMID: 28525555.

Farokhnia M, Schwandt ML, Lee MR, Bollinger JW, Farinelli LA, Amodio JP, Sewell L, Lionetti TA, Spero DE, Leggio L. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017 Apr 25;7(4): e1108. doi: 10.1038/tp.2017.71. PubMed PMID: 28440812; PubMed Central PMCID: PMC5416708.

Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017 Jul;112(7):1173-1183. doi: 10.1111/add.13787. Epub 2017 Apr 2. PubMed PMID: 28192622.

Beraha EM, Salemink E, Goudriaan AE, Bakker A, de Jong D, Smits N, Zwart JW, Geest DV, Bodewits P, Schiphof T, Defourny H, van Tricht M, van den Brink W,

Wiers RW. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016 Dec; 26(12):1950-1959. doi: 10.1016/j.euroneuro.2016.10.006. Epub 2016 Nov 11. PubMed PMID: 27842939.

Gupta M, Verma P, Rastogi R, Arora S, Elwadhi D. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. Am J Drug Alcohol Abuse. 2017 May;43(3):324-331. doi: 10.1080/00952990.2016.1240797. Epub 2016 Nov 3. PubMed PMID: 27808555.

Vourc'h M, Feuillet F, Mahe PJ, Sebille V, Asehnoune K; BACLOREA trial group. Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial. Trials. 2016 Aug 19;17(1):415.

doi: 10.1186/s13063-016-1539-2. PubMed PMID: 27542731; PubMed Central PMCID: PMC4992221.

Girish K, Vikram Reddy K, Pandit LV, Pundarikaksha HP, Vijendra R, Vasundara K, Manjunatha R, Nagraj M, Shruthi R. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Biomed J. 2016 Feb;39(1):72-80. doi: 10.1016/j.bj.2015.09.002. Epub 2016 Mar 25. PubMed PMID: 27105601; PubMed Central PMCID: PMC6138810.

Krupitsky EM, Rybakova KV, Kiselev AS, Alexeeva YV, Berntsev VA, Chekhlaty EI, Zubova EY, Popov YV, Neznanov NG. [Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):53-62. doi: 10.17116/jnevro20151156153-62. Russian. PubMed PMID: 26356398.

Müller CA, Geisel O, Pelz P, Higl V, Krüger J, Stickel A, Beck A, Wernecke KD, Hellweg R, Heinz A. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1167-77. doi: 10.1016/j.euroneuro.2015.04.002. Epub 2015 Apr 14. PubMed PMID: 26048580.

Inada T. [Drug-Induced Akathisia]. Brain Nerve. 2017 Dec;69(12):1417-1424. doi: 10.11477/mf.1416200927. Japanese. PubMed PMID: 29282345.

Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003 Jun;23(3):305-8. PubMed PMID: 12826992.

Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol. 2001 Dec;21(6):612-5. PubMed PMID: 11763011.

Weiss D, Aizenberg D, Hermesh H, Zemishlany Z, Munitz H, Radwan M, Weizman A. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry. 1995 Oct;167(4):483-6. PubMed PMID: 8829717.

Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry. 2001 Jul; 179: 4-8. PubMed PMID: 11435260.

Smith SL, Grelotti DJ, Fils-Aime R, Uwimana E, Ndikubwimana JS, Therosme T, Severe J, Dushimiyimana D, Uwamariya C, Bienvenu R, Alcindor Y, Eustache E,

Raviola GJ, Fricchione GL. Catatonia in resource-limited settings: a case series and treatment protocol. Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):89-93. doi: 10.1016/j.genhosppsych.2014.10.009. Epub 2014 Oct 30. PubMed PMID: 25467078; PubMed Central PMCID: PMC4304795.

Chiou YJ, Lee Y, Lin CC, Huang TL. A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review. Medicine (Baltimore). 2015 Oct;94(43): e1752. doi: 10.1097/MD.0000000000001752. Review. PubMed PMID: 26512569; PubMed Central PMCID: PMC4985383.

Lin CC, Hung YY, Tsai MC, Huang TL. Relapses and recurrences of catatonia: 30-case analysis and literature review. Compr Psychiatry. 2016 Apr; 66: 157-65. doi: 10.1016/j.comppsych.2016.01.011. Epub 2016 Jan 23. PubMed PMID: 26995249.

Madigand J, Lebain P, Callery G, Dollfus S. Catatonic syndrome: From detection to therapy. Encephale. 2016 Aug;42(4):340-5. doi: 10.1016/j.encep.2015.09.008. Epub 2016 May 20. Review. PubMed PMID: 27216588.

Iriondo O, Zaldibar-Gerrikagoitia J, Rodríguez T, García JM, Aguilera L. Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis. Rev Esp Anestesiol Reanim. 2017 Mar;64(3):172-176. doi: 10.1016/j.redar.2016.09.004. Epub 2016 Dec 2. English, Spanish. PubMed PMID: 27919412.

Lin CC, Hung YY, Tsai MC, Huang TL. The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry. PLoS One. 2017 Jan

23;12(1):e0170452. doi: 10.1371/journal.pone.0170452. eCollection 2017. PubMed PMID: 28114315; PubMed Central PMCID: PMC5256942.

Duncan-Azadi CR, Johnson PN, Gormley A. Case Report of Midazolam Withdrawal-Induced Catatonia in a 9-Year-Old Patient. A A Case Rep. 2017 May 1;8(9):242-245. doi: 10.1213/XAA.0000000000000482. PubMed PMID: 28181946.

Ohi K, Kuwata A, Shimada T, Yasuyama T, Nitta Y, Uehara T, Kawasaki Y. Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report. Medicine (Baltimore). 2017 Apr;96(16):e6566. doi: 10.1097/MD.0000000000006566. PubMed PMID: 28422845; PubMed Central PMCID: PMC5406061.

Chen RA, Huang TL. Periodic catatonia with long-term treatment: a case report. BMC Psychiatry. 2017 Sep 29;17(1):337. doi: 10.1186/s12888-017-1497-6. PubMed PMID: 28962597; PubMed Central PMCID: PMC5622437.

Tseng WT, Huang TL. Excited catatonia in a patient with fatal pulmonary embolism and a successful treatment strategy. BMC Psychiatry. 2018 Oct 19;18(1):342. doi: 10.1186/s12888-018-1925-2. PubMed PMID: 30340477; PubMed Central PMCID: PMC6194636.

Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 26; 3: CD000206. doi: 10.1002/14651858.CD000206.pub4. Review. PubMed PMID: 29578611.

Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000206. Review. PubMed PMID: 10796323.

Loonen AJ, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric

inpatients? A negative, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1992 Feb;12(1):39-42. PubMed PMID: 1348061.

Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1990 Dec;10(6):414-6. PubMed PMID: 1981070.

Halabe Bucay A. Donepezil (aricept) as a treatment for anorexia nervosa: a very feasible therapeutic possibility. Expert Opin Investig Drugs. 2009 May;18(5):569-71. doi: 10.1517/13543780902810360. Review. PubMed PMID: 19388874.

Dasuri K, Zhang L, Kim SO, Bruce-Keller AJ, Keller JN. Dietary and donepezil modulation of mTOR signaling and neuroinflammation in the brain. Biochim Biophys Acta. 2016 Feb;1862(2):274-83. doi: 10.1016/j.bbadis.2015.11.002. Epub 2015 Nov 10. PubMed PMID: 26554604; PubMed Central PMCID: PMC4959420.

Baandrup L, Glenthøj BY, Jennum PJ. Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Res. 2016 Jun 30; 240: 163-169. doi: 10.1016/j.psychres.2016.04.031. Epub 2016 Apr 15. PubMed PMID: 27107670.

Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Feb;68(2):237-41. PubMed PMID: 17335321.

Shamir E, Rotenberg VS, Laudon M, Zisapel N, Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol. 2000 Dec;20(6):691-4. PubMed PMID: 11106143.

Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000 May;61(5):373-7. PubMed PMID: 10847313.

Stummer L, Markovic M, Maroney ME. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines (Basel). 2018 Aug 11;5(3). pii: E88. doi: 10.3390/medicines5030088. Review. PubMed PMID: 30103483; PubMed Central PMCID: PMC6165340.

Oliveira P, Coroa M, Madeira N. Treatment Options for Insomnia in Schizophrenia: A Systematic Review. Pharmacopsychiatry. 2018 Jul 30. doi: 10.1055/a-0658-1645. [Epub ahead of print] PubMed PMID: 30060263.

Monti JM, BaHammam AS, Pandi-Perumal SR, Bromundt V, Spence DW, Cardinali DP, Brown GM. Sleep and circadian rhythm dysregulation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3; 43: 209-16. doi: 10.1016/j.pnpbp.2012.12.021. Epub 2013 Jan 11. Review. PubMed PMID: 23318689.

Andrade C, Suresh Kumar PN. Treating residual insomnia in schizophrenia: examining the options. Acta Psychiatr Scand. 2013 Jan;127(1):11. doi: 10.1111/acps.12019. PubMed PMID: 23240596.

Afonso P, Figueira ML, Paiva T. Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract. 2011 Nov;15(4):311-5. doi: 10.3109/13651501.2011.605954. Epub 2011 Aug 28. PubMed PMID: 22122006.

Kantrowitz J, Citrome L, Javitt D. GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications. CNS Drugs. 2009 Aug;23(8):681-91. doi:

10.2165/00023210-200923080-00005. Review. PubMed PMID: 19594197; PubMed Central PMCID: PMC4988234.

Benson KL. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am. 2006 Dec;29(4):1033-45; abstract ix-x. Review. PubMed PMID: 17118280.

Efron D, Lycett K, Sciberras E. Use of sleep medication in children with ADHD.Sleep Med. 2014 Apr;15(4):472-5. doi: 10.1016/j.sleep.2013.10.018. Epub 2014 Feb 7. PubMed PMID: 24684977.

Campos Costa I, Nogueira Carvalho H, Fernandes L. Aging, circadian rhythms and depressive disorders: a review. Am J Neurodegener Dis. 2013 Nov 29;2(4):228-46. Review. PubMed PMID: 24319642; PubMed Central PMCID: PMC3852564

Vellante F, Cornelio M, Acciavatti T, Cinosi E, Marini S, Dezi S, De Risio L, Di Iorio G, Martinotti G, Di Giannantonio M. Treatment of resistant insomnia and major depression. Clin Ter. 2013;164(5):429-35. doi: 10.7417/CT.2013.1609. Review. PubMed PMID: 24217831.

Bartlett DJ, Biggs SN, Armstrong SM. Circadian rhythm disorders among adolescents: assessment and treatment options. Med J Aust. 2013 Oct 21;199(8): S16-20. Review. PubMed PMID: 24138360.

Rondanelli M, Faliva MA, Perna S, Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013 Oct;25(5):499-510. doi: 10.1007/s40520-013-0118-6. Epub 2013 Sep 18. Review. PubMed PMID: 24046037; PubMed Central PMCID: PMC3788186.

Srinivasan V, Zakaria R, Othaman Z, Brzezinski A, Prasad A, Brown GM. Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders. CNS Neurol Disord Drug Targets. 2012 Mar;11(2):180-9. Review. PubMed PMID: 22483286.

Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2017 Nov; 56(11): 948-957.e4. doi: 10.1016/j.jaac.2017.09.414. Epub 2017 Sep 19. PubMed PMID: 29096777.

Sletten TL, Magee M, Murray JM, Gordon CJ, Lovato N, Kennaway DJ, Gwini SM, Bartlett DJ, Lockley SW, Lack LC, Grunstein RR, Rajaratnam SMW; Delayed Sleep on Melatonin (DelSoM) Study Group. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomized clinical trial. PLoS Med. 2018 Jun 18;15(6): e1002587. doi: 10.1371/journal.pmed.1002587. eCollection 2018 Jun. PubMed PMID: 29912983; PubMed Central PMCID: PMC6005466.

Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial. BMC Med. 2018 Jan 19; 16(1): 8. doi: 10.1186/s12916-017-0995-1. PubMed PMID: 29347988; PubMed Central PMCID: PMC5774131.

Baandrup L, Glenthøj BY, Jennum PJ. Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Res. 2016 Jun 30; 240: 163-169. doi: 10.1016/j.psychres.2016.04.031. Epub 2016 Apr 15. PubMed PMID: 27107670.

Eckerberg B, Lowden A, Nagai R, Akerstedt T. Melatonin treatment effects on adolescent students' sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012 Nov;29(9):1239-48. doi: 10.3109/07420528.2012.719962. Epub 2012 Sep 24. PubMed PMID: 23005039.

Lewis SR, Pritchard MW, Schofield-Robinson OJ, Alderson P, Smith AF. Melatonin for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev. 2018 May 10;5:CD012455. doi: 10.1002/14651858.CD012455.pub2. Review. PubMed PMID: 29746721; PubMed Central PMCID: PMC6353085.

Ophoff D, Slaats MA, Boudewyns A, Glazemakers I, Van Hoorenbeeck K, Verhulst SL. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018 May;177(5):641-648. doi: 10.1007/s00431-018-3116-z. Epub 2018 Mar 3. Review. PubMed PMID: 29502303.

Pievsky MA, McGrath RE. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis. Neurosci Biobehav Rev. 2018 Jul; 90: 447-455. doi: 10.1016/j.neubiorev.2018.05.012. Epub 2018 May 8. Review. PubMed PMID: 29751051.

De Crescenzo F, Cortese S, Adamo N, Janiri L. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017 Feb;20(1):4-11. doi: 10.1136/eb-2016-102415. Epub 2016 Dec 19. Review. PubMed PMID: 27993933.

Fredriksen M, Peleikis DE. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):23-31. doi: 10.1111/bcpt.12477. Epub 2015 Sep 24. Review. PubMed PMID: 26404187.

Simon N, Rolland B, Karila L. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders. Curr Pharm Des. 2015; 21(23): 3359-66. Review. PubMed PMID: 26088112.

Retz W, Retz-Junginger P. Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S 35-43. doi: 10.1007/s00406-014-0542-4. Epub 2014 Sep 18. Review. PubMed PMID: 25231833.

Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD005041. PubMed PMID: 25230710.

Weisler RH, Stark JG, Sikes C. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD. Clin Pharmacol Drug Dev. 2018 Feb;7(2):160-167. doi: 10.1002/cpdd.361. Epub 2017 May 25. PubMed PMID: 28544344.

Tebartz van Elst L, Maier S, Klöppel S, Graf E, Killius C, Rump M, Sobanski E, Ebert D, Berger M, Warnke A, Matthies S, Perlov E, Philipsen A. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. J Psychiatry Neurosci. 2016 Oct;41(6):422-430. PubMed PMID: 27575717; PubMed Central PMCID: PMC5082513.

Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):10-18. doi: 10.1089/cap.2017.0044. Epub 2017 Oct 17. PubMed PMID: 29039979; PubMed Central PMCID: PMC5771548.

Schrantee A, Tamminga HG, Bouziane C, Bottelier MA, Bron EE, Mutsaerts HJ, Zwinderman AH, Groote IR, Rombouts SA, Lindauer RJ, Klein S, Niessen WJ, Opmeer

BC, Boer F, Lucassen PJ, Andersen SL, Geurts HM, Reneman L. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2016 Sep 1;73(9):955-62. doi: 10.1001/jamapsychiatry.2016.1572. PubMed PMID: 27487479; PubMed Central PMCID: PMC5267166.

Inada T. [Drug-Induced Akathisia]. Brain Nerve. 2017 Dec;69(12):1417-1424. doi: 10.11477/mf.1416200927. Japanese. PubMed PMID: 29282345.

Aggarwal A, Khandelwal A, Garg A, Jiloha RC. Akathisia associated with mianserin. J Clin Psychopharmacol. 2010 Jun; 30(3): 338-9. doi: 10.1097/JCP.0b013e3181dcf1c2. PubMed PMID: 20473077.

Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010 Feb;196(2):89-91. doi: 10.1192/bjp.bp.109.070540. PubMed PMID: 20118449.

Stryjer R, Grupper D, Strous R, Poyurovsky M, Weizman A. Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. Eur Psychiatry. 2004 Jun; 19(4): 237-8. PubMed PMID: 15196609.

Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry. 2001 Jul; 179: 4-8. PubMed PMID: 11435260.

Westerlund M. [A case report. Improvement in a patient with severe akathisia achieved by mianserin]. Lakartidningen. 2000 Oct 4;97(40):4474. Swedish. PubMed PMID: 11068403.

Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry. 1999 Mar; 174: 238-42. PubMed PMID: 10448449.

Poyurovsky M, Fuchs C, Weizman A. Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol. 1998 Jun;18(3):253-4. PubMed PMID: 9617987.

Poyurovsky M, Weizman A. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int Clin Psychopharmacol. 1997 Sep;12(5):263-8. PubMed PMID: 9466160.

Poyurovsky M, Weizman A. Selective serotonin reuptake inhibitor and akathisia. J Clin Psychopharmacol. 1997 Dec;17(6):489. PubMed PMID: 9408813.

Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging. 1997 May;10(5):367-83. Review. PubMed PMID: 9143857.

Poyurovsky M, Kosov A, Halperin E, Enoch D, Schneidman M, Weizman A. Akathisia-like behavior following ECT, and its successful treatment with low-dose mianserin. Int Clin Psychopharmacol. 1995 Nov;10(4):257-60. PubMed PMID: 8748048.

Poyurovsky M, Meerovich I, Weizman A. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol. 1995 Jun;10(2):111-4. PubMed PMID: 7673653.

Poyurovsky M, Kreinin A, Modai I, Weizman A. Lithium-induced akathisia responds to low-dose mianserin: case report. Int Clin Psychopharmacol. 1995 Nov; 10(4): 261-3. PubMed PMID: 8748049.

Talih F, Ghossoub E. Moxonidine for tramadol withdrawal symptoms during detoxification. BMJ Case Rep. 2015 Jul 8;2015. pii: bcr2015210444. doi: 10.1136/bcr-2015-210444. PubMed PMID: 26156837; PubMed Central PMCID: PMC4499750.

Li F, Wu N, Su RB, Liu Y, Lu XQ, Li J. Comparison of agmatine with moxonidine and rilmenidine in morphine dependence in vitro: role of imidazoline I(1) receptors. Eur J Pharmacol. 2009 Jun 10;612(1-3):1-8. doi: 10.1016/j.ejphar.2009.03.077. Epub 2009 Apr 6. PubMed PMID: 19356733.

Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000206. Review. PubMed PMID: 10796323.

Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ. A clinical trial of nifedipine

in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav. 1991 Jul;39(3):743-5. PubMed PMID: 1686106.

Stedman TJ, Whiteford HA, Eyles D, Welham JL, Pond SM. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol. 1991 Feb;11(1):43-7. PubMed PMID: 1674950.

Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1990 Dec;10(6):414-6. PubMed PMID: 1981070.

Cipriani A, Saunders K, Attenburrow MJ, Stefaniak J, Panchal P, Stockton S, Lane TA, Tunbridge EM, Geddes JR, Harrison PJ. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016 Oct;21(10):1324-32. doi: 10.1038/mp.2016.86. Epub 2016 May 31. Review. PubMed PMID: 27240535; PubMed Central PMCID: PMC5030455.

Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord. 2000 Jun;2(2):108-19. Review. PubMed PMID: 11252650.

Post RM, Frye MA, Denicoff KD, Leverich GS, Dunn RT, Osuch EA, Speer AM, Obrocea G, Jajodia K. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disord. 2000 Dec;2(4):305-15. Review. PubMed PMID: 11252642.

Sarfati Y, Spadone C, Vanelle JM, Lôo H. [Calcium antagonists and lithium in preventive treatment of manic-depressive disorder]. Encephale. 1996 Mar-Apr;22(2):149-53. Review. French. PubMed PMID: 8706625.

Kidd PM. Bipolar disorder and cell membrane dysfunction. Progress toward integrative management. Altern Med Rev. 2004 Jun;9(2):107-35. Review. PubMed PMID: 15253674.

Keers R, Farmer AE, Aitchison KJ. Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. Psychol Med. 2009 Aug; 39(8): 1231-5. doi: 10.1017/S0033291708005084. Epub 2009 Feb 12. Review. PubMed PMID: 19215628.

Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, Luckenbaugh D. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol. 1998 Oct;18(5):404-13. PubMed PMID: 9790159.

Pazzaglia PJ, George MS, Post RM, Rubinow DR, Davis CL. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology. 1995 Aug;13(1):75-83. PubMed PMID: 8526973.

Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993 Dec;49(3):257-72. PubMed PMID: 8177920.

Manna V. [Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion]. Minerva Med. 1991 Nov;82(11):757-63. Italian. PubMed PMID: 1766578.

Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol. 1990 Jun;13(3):224-8. PubMed PMID: 2192795.

Takeuchi I, Hanya M, Uno J, Fujita K, Kamei H. Effectiveness of the repeated administration of scopolamine ointment on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: A preliminary study. Asia Pac Psychiatry. 2017 Dec;9(4). doi: 10.1111/appy.12269. Epub 2016 Dec 19. PubMed PMID: 29193710.

Táboas-Pereira MA, Paredes-Mercado C, Alonso-Curcó X, Badosa-Pagès J, Muchart J, Póo P. [Drooling therapy in children with neurological disorders]. Rev Neurol. 2015 Jul 16 ;61(2) :66-70. Spanish. PubMed PMID: 26156441.

Franco JB, Cacita N, Freua KA, Ortega KL, de Melo Peres MPS. Treatment of drooling with scopolamine in pediatric ICU: A case series report. Spec Care Dentist. 2018 Nov;38(6):362-366. doi: 10.1111/scd.12326. Epub 2018 Sep 20. PubMed PMID: 30238487.

Chowdhury NA, Sewatsky ML, Kim H. Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population. Am J Phys Med Rehabil. 2017 Aug;96(8: e151-e154. doi:

10.1097/PHM.0000000000000665. PubMed PMID: 28081025.

Goto T, Kato M, Matsumura Y, Omata N, Yoshida M, Watanabe K, Takahashi T, Higashima M, Wada Y. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report. J Clin Psychopharmacol. 2017 Feb; 37(1): 106-107. doi: 10.1097/JCP.0000000000000613. PubMed PMID: 27846048.

Chaléat-Valayer E, Porte M, Buchet-Poyau K, Roumenoff-Turcant F, D'Anjou MC, Boulay C, Bernard JC, Touzet S. Management of drooling in children with cerebral palsy: A French survey. Eur J Paediatr Neurol. 2016 Jul;20(4):524-31. doi: 10.1016/j.ejpn.2016.04.010. Epub 2016 Apr 22. PubMed PMID: 27155820.

McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord. 2019 Mar 1; 246: 217-223. doi: 10.1016/j.jad.2018.12.023. Epub 2018 Dec 17. PMID: 30583148.

Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. PMID: 28320223

Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018 May 14; 12: 1215-1238. doi: 10.2147/DDDT.S133205. eCollection 2018. Review. PMID: 29795977; Central PMCID: PMC5958944.

Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208. doi: 10.1002/14651858.CD000208.pub2. Review. PMID: 29552749.

Niemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x. Review. Erratum in: Drugs. 2018 Mar 10. Dosage error in article text. PMID: 29484607.

Morrow T. Two New Drugs for Tardive Dyskinesia Hit the Market. Manag Care. 2018 Jan;27(1):35-36. PMID: 29369770.

El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 18;1:CD000458. doi: 10.1002/14651858.CD000458.pub3. Review. PMID: 29342497.

Cummings MA, Proctor GJ, Stahl SM. Deuterium Tetrabenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. 2018 Jan;11(4):214-220. doi: 10.3371/CSRP.CUPR.010318. Review. PMID: 29341821.

Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017 Sep/Oct;78(8):1136-1147. doi: 10.4088/JCP.tv17016ah4c. Review. PMID: 29022654.

Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review. PMID: 28044943.

Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review. PMID: 27819145.

Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May;76(7):779-87. doi: 10.1007/s40265-016-0568-1. Review. PubMed PMID: 27091214.

Seigneurie AS, Sauvanaud F, Limosin F. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Encephale. 2016 Jun;42(3):248-54. doi: 10.1016/j.encep.2015.12.021. PMID: 26922134.

Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 26;3:CD000206. doi:

10.1002/14651858.CD000206.pub4. Review. PubMed PMID: 29578611.

Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000206. Review. PubMed PMID: 10796323.

Bartko G, Horvath S, Zador G, Frecska E. Effects of adjunctive verapamil administration in chronic schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(3):343-9. PubMed PMID: 1677775.

Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry. 1989 Jan;50(1):26-7. PubMed PMID: 2562952.

Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M. Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res. 2000 Feb 14;93(1):83-7. PubMed PMID: 10699232.

Mallinger AG, Thase ME, Haskett R, Buttenfield J, Luckenbaugh DA, Frank E, Kupfer DJ, Manji HK. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord. 2008 Dec;10(8):856-66. doi: 10.1111/j.1399-5618.2008.00636.x. PubMed PMID: 19594501; PubMed Central PMCID: PMC3387673.

Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry. 1990 Aug;51 Suppl:9-16; discussion 17-9. Review. PubMed PMID: 2116406.

Cipriani A, Saunders K, Attenburrow MJ, Stefaniak J, Panchal P, Stockton S, Lane TA, Tunbridge EM, Geddes JR, Harrison PJ. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016 Oct;21(10):1324-32. doi: 10.1038/mp.2016.86. Epub 2016 May 31. Review. PubMed PMID: 27240535; PubMed Central PMCID: PMC5030455.

Leo RJ, Singh J. Migraine headache and bipolar disorder comorbidity: A systematic review of the literature and clinical implications. Scand J Pain. 2016 Apr; 11: 136-145. doi: 10.1016/j.sjpain.2015.12.002. Epub 2016 Feb 23. Review. PubMed PMID: 28850455.

Keers R, Farmer AE, Aitchison KJ. Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. Psychol Med. 2009 Aug;39(8):1231-5. doi: 10.1017/S0033291708005084. Epub 2009 Feb 12. Review. PubMed PMID: 19215628.

Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev. 2003 Mar-Apr;11(2):73-93. Review. PubMed PMID: 12620132.

Barrios C, Chaudhry TA, Goodnick PJ. Rapid cycling bipolar disorder. Expert Opin Pharmacother. 2001 Dec;2(12):1963-73. Review. PubMed PMID: 11825328.

Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord. 2000 Jun;2(2):108-19. Review. PubMed PMID: 11252650.

Hollister LE, Trevino ES. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J Psychiatry. 1999 Sep;44(7):658-64. Review. PubMed PMID: 10500866.

Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry. 1998 Jul;155(7):972-3. PubMed PMID: 9659868.

Amorim E, McDade EM. Rapidly-progressive catatonia responsive to zolpidem in a patient with ovarian teratoma-associated paraneoplastic encephalitis. J Clin Neurosci. 2016 Aug; 30: 136-138. doi: 10.1016/j.jocn.2016.01.028. Epub 2016 Mar 7. PubMed PMID: 26964475.

Madigand J, Lebain P, Callery G, Dollfus S. Catatonic syndrome: From detection to therapy. Encephale. 2016 Aug;42(4):340-5. doi: 10.1016/j.encep.2015.09.008. Epub 2016 May 20. Review. PubMed PMID: 27216588.

Javelot H, Michel B, Steiner R, Javelot T, Cottencin O. Zolpidem test and catatonia. J Clin Pharm Ther. 2015 Dec;40(6):699-701. doi: 10.1111/jcpt.12330. Epub 2015 Nov 7. PubMed PMID: 26547135.

Bastiampillai T, McGovern V, Lloyd B, Hittur Lingappa S, Nelson A. Treatment refractory

chronic catatonia responsive to zolpidem challenge. Aust N Z J Psychiatry. 2016 Jan;50(1):98. doi: 10.1177/0004867415582232. Epub 2015 Apr 23. PubMed PMID: 25907270.

Pot AL, Lejoyeux M. [Catatonia]. Encephale. 2015 Jun; 41(3):274-9. doi: 10.1016/j.encep.2015.03.001. Epub 2015 Apr 7. Review. French. PubMed PMID: 25858694.

Hlal H, Kettani N, Berhili N, Rammouz I, Aalouane R. [The role of zolpidem in improving catatonic schizophrenia. Case report]. Presse Med. 2014 Sep;43(9):1018-20. doi: 10.1016/j.lpm.2013.11.023. Epub 2014 Apr 13. French. PubMed PMID: 24726030.

Peglow S, Prem V, McDaniel W. Treatment of catatonia with zolpidem. J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E13. doi: 10.1176/appi.neuropsych.11120367. PubMed PMID: 24026726.

Isomura S, Monji A, Sasaki K, Baba S, Onitsuka T, Ohara T, Mizoguchi Y, Kato TA, Horikawa H, Seki Y, Kanba S. FTD with catatonia-like signs that temporarily resolved with zolpidem. Neurol Clin Pract. 2013 Aug;3(4):354-357. doi: 10.1212/CPJ.0b013e318296f263. PubMed PMID: 29473615; PubMed Central PMCID: PMC5765963.

Hsieh MH, Chen TC, Chiu NY, Chang CC. Zolpidem-related withdrawal catatonia: a case report. Psychosomatics. 2011 Sep-Oct;52(5):475-7. doi: 10.1016/j.psym.2011.01.024. PubMed PMID: 21907070.

Cottencin O, Danel T, Goudemand M, Thomas P, Consoli SM. Catatonia recognition and treatment. Med Sci Monit. 2009 Aug;15(8):CS129-31. PubMed PMID: 19644424.

Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet. 1997 Jun 28;349(9069):1914. PubMed PMID: 9217783.

Thomas P, Rascle C, Mastain B, Maron M, Vaiva G. Test for catatonia with zolpidem. Lancet. 1997 Mar 8;349(9053):702. PubMed PMID: 9078210.

Mastain B, Vaiva G, Guerouaou D, Pommery J, Thomas P. [Favourable effect of zolpidem on catatonia]. Rev Neurol (Paris). 1995 Jan;151(1):52-6. French. PubMed PMID: 7676130.

Naguy A, Al-Enezi N. Lamotrigine Uses in Psychiatric Practice. Am J Ther. 2019 Jan/Feb;26(1): e96-e102. doi: 10.1097/MJT.0000000000000535. Review. PubMed PMID: 30601211.

Scripter C. Headache: Tension-Type Headache. FP Essent. 2018 Oct; 473: 17-20. Review. PubMed PMID: 30346680.

Poyurovsky M, Weizman A. Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia. J Clin Psychopharmacol. 2018 Dec; 38(6): 609-611. doi: 10.1097/JCP.0000000000000972. PubMed PMID: 30300293.

Limandri BJ. Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches. J Psychosoc Nurs Ment Health Serv. 2018 Oct 1;56(10):11-14. doi: 10.3928/02793695-20180920-02. PubMed PMID: 30278095.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053129.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053130.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053131.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053132.

The Lancet Neurology. Difficult choices in treating Parkinson's disease psychosis. Lancet Neurol. 2018 Jul;17(7):569. doi: 10.1016/S1474-4422(18)30209-6. Epub 2018 May 29. PubMed PMID: 29858161.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053133.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053134.

Hamed SA. Sexual Dysfunctions Induced by Pregabalin. Clin Neuropharmacol. 2018 Jul/Aug;41(4):116-122. doi: 10.1097/WNF.0000000000000286. PubMed PMID: 30001248.

The Lancet Neurology. Difficult choices in treating Parkinson's disease psychosis. Lancet Neurol. 2018 Jul;17(7):569. doi: 10.1016/S1474-4422(18)30209-6. Epub 2018 May 29. PubMed PMID: 29858161.

Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O. [Off-label use of psychotropic medications in pediatric wards: a prospective study]. Arch Pediatr. 2009 Sep;16(9):1252-60. doi: 10.1016/j.arcped.2009.06.012. Epub 2009 Jul 28. French. PubMed PMID: 19640689.

Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28. Review. PubMed PMID: 28300462.

Chon MW, Lee J, Chung S, Kim Y, Kim HW. Prescription Pattern of Antidepressants for Children and Adolescents in Korea Based on Nationwide Data. J Korean Med Sci. 2017 Oct;32(10):1694-1701. doi: 10.3346/jkms.2017.32.10.1694. PubMed PMID: 28875616; PubMed Central PMCID: PMC5592186.

Chee KY, Tripathi A, Avasthi A, Chong MY, Xiang YT, Sim K, Kanba S, He YL, Lee MS, Chiu HF, Yang SY, Kuga H, Udomratn P, Tanra AJ, Maramis MM, Grover S,

Mahendran R, Kallivayalil RA, Shen WW, Shinfuku N, Tan CH, Sartorius N. Prescribing Pattern of Antidepressants in Children and Adolescents: Findings from the Research on Asia Psychotropic Prescription Pattern. East Asian Arch Psychiatry. 2016 Mar;26(1):10-7. PubMed PMID: 27086755.

Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422. Review. PubMed PMID: 26159445.

Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, Fagiolini A. Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Curr Pharm Des. 2015;21(23):3343-51. Review. PubMed PMID: 26088119.

Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014 Sep;75(9):1010-8. doi: 10.4088/JCP.13r08851. Review. PubMed PMID: 25295426.

Cui JF, Yang W, Xie YM, Sun Y, Zhuang Y, Wang YY. [Real-world analysis of concurrent diseases and medicine use among patients with insomnia]. Zhongguo Zhong Yao Za Zhi. 2014 Sep;39(18):3519-26. Chinese. PubMed PMID: 25532388.

Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, Boxer A. Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease. Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):182-9. doi: 10.1097/WAD.0b013e3182a7159d. PubMed PMID: 23995817; PubMed Central PMCID: PMC3938980.

Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Pharmacotherapy in depressed children and adolescents. World J Biol Psychiatry. 2011 Sep;12 Suppl 1:11-5. doi: 10.3109/15622975.2011.600295. Review. PubMed PMID: 21905988.

Mathy F, Malchair A. [Prescriptions in child psychiatry, on the use of antipsychotic drugs for children and Adolescents]. Rev Med Liege. 2018 Feb;73(2):94-100. French. PubMed PMID: 29517873.

Bain KT, Schwartz EJ, Chan-Ting R. Reducing Off-Label Antipsychotic Use in Older Community-Dwelling Adults With Dementia: A Narrative Review. J Am Osteopath Assoc. 2017 Jul 1;117(7):441-450. doi: 10.7556/jaoa.2017.090. Review. PubMed PMID: 28662557.

Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS. Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children? : A Time-Trend Analysis. PLoS One. 2016 Mar 31;11(3): e0152195. doi: 10.1371/journal.pone.0152195. eCollection 2016. PubMed PMID: 27032095; PubMed Central PMCID: PMC4816295.

El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016 Feb;41(1):7-18. doi: 10.1111/jcpt.12357. Review. PubMed PMID: 26813985.

Hatta K, Kishi Y, Wada K, Odawara T, Takeuchi T, Shiganami T, Tsuchida K, Oshima Y, Uchimura N, Akaho R, Watanabe A, Taira T, Nishimura K, Hashimoto N, Usui C, Nakamura H. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study. Int J Geriatr Psychiatry. 2014 Mar;29(3):253-62. doi: 10.1002/gps.3999. Epub 2013 Jun 25. PubMed PMID: 23801358; PubMed Central PMCID: PMC4229063.

Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, Seok JH. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013 Sep 30; 13: 240. doi: 10.1186/1471-244X-13-240. PubMed PMID: 24074357; PubMed Central PMCID: PMC3849610.

Marras C, Gruneir A, Wang X, Fischer H, Gill SS, Herrmann N, Anderson GM, Hyson C, Rochon PA. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry. 2012 Feb;20(2):149-58. doi: 10.1097/JGP.0b013e3182051bd6. PubMed PMID: 22273735.

Pisa FE, Cosano G, Giangreco M, Giorgini T, Biasutti E, Barbone F; Group for the Study of Medication Use in Centers for Post-acute Brain Injury Rehabilitation. Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: a cross-sectional survey. Brain Inj. 2015;29(4):508-16. doi: 10.3109/02699052.2014.992474. Epub 2014 Dec 30. PubMed PMID: 25549155.

Evangelista E, Lopez R, Dauvilliers Y. Update on treatment for idiopathic hypersomnia. Expert Opin Investig Drugs. 2018 Feb;27(2):187-192. doi: 10.1080/13543784.2018.1417385. Epub 2018 Jan 3. Review. PubMed PMID: 29250981.

Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017 Jun;18(8):809-817. doi: 10.1080/14656566.2017.1323877. Epub 2017 May 17. Review. PubMed PMID: 28443381.

Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One. 2018 Jul 19;13(7): e0198363. doi: 10.1371/journal.pone.0198363. eCollection 2018. PubMed PMID: 30024873; PubMed Central PMCID: PMC6053129.